SHEILA RITTENBERG

Access to care for people with psoriasis and psoriatic arthritis H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011

H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SECTION 4. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION Authorizes the Centers for Disease Control and Prevention (CDC) to undertake psoriasis and psoriatic arthritis data collection efforts including: incorporating questions into existing public health surveys, questionnaires and other databases to collect information regarding prevalence in the United States, age of onset, health-related quality of life, health care utilization, burden of disease (employment, work, etc.), direct and indirect costs, health disparities (age, gender, racial, ethnic), comorbidities and natural history of disease. These efforts may include the consideration and development of a patient registry, which would include individuals of all ages. SECTION 5. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS Non-binding language that: Recognizes that the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases. Commends the non-profit and private sector psoriasis research communities for planning a multi-disciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions. Encourages the National Institutes of Health (NIH) to continue to work with the organizations and private sector stakeholders who convene the multi-disciplinary scientific meeting to discuss future directions of psoriasis and comorbid research. Suggests that the non-profit and private sector meeting conveners disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from NIH and other relevant federal agencies. Encourages the Secretary of the Department of Health and Human Services (HHS), acting through the Director of the NIH, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases (NIAMS) and other NIH institutes and centers, to utilize the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research and to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged.

Access to care for people with psoriasis and psoriatic arthritis H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011

Access to care for people with psoriasis and psoriatic arthritis H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011

H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SEC. 3. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION. (a) In General- The Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention, is authorized to undertake psoriasis and psoriatic arthritis data collection efforts, including incorporating questions into public health surveys, questionnaires, and other databases in existence as of the date of the enactment of this Act to collect information, with respect to psoriasis and psoriatic arthritis, regarding-- (1) the prevalence of psoriasis and psoriatic arthritis in the United States; (2) the age of onset; (3) health-related quality of life; (4) health care utilization; (5) burden of such disease (such as with respect to employment); (6) direct and indirect costs; (7) health disparities, including with respect to age, gender, race, and ethnicity; and (8) comorbidities and the natural history of such disease. Such data collection efforts may include the consideration and development of a patient registry, which would include individuals of all ages. (b) Authorization of Appropriations- To carry out subsection (a), there are authorized to be appropriated $1,500,000 for each of fiscal years 2012 through 2017. SEC. 4. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS. It is the sense of the Congress that-- (1) the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases; (2) the nonprofit and private sector psoriasis research communities are to be commended for planning a multidisciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions; (3) the National Institutes of Health is encouraged to continue to work with the organizations and private sector stakeholders who convene the multidisciplinary scientific meeting to discuss future directions of psoriasis and comorbid research; (4) the nonprofit and private sector meeting conveners should disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from the National Institutes of Health and other relevant Federal agencies; and (5) utilizing the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research, the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases and other institutes and centers of the National Institutes of Health, is encouraged to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged.

Access to care for people with psoriasis and psoriatic arthritis H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011

H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SECTION 4. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION Authorizes the Centers for Disease Control and Prevention (CDC) to undertake psoriasis and psoriatic arthritis data collection efforts including: incorporating questions into existing public health surveys, questionnaires and other databases to collect information regarding prevalence in the United States, age of onset, health-related quality of life, health care utilization, burden of disease (employment, work, etc.), direct and indirect costs, health disparities (age, gender, racial, ethnic), comorbidities and natural history of disease. These efforts may include the consideration and development of a patient registry, which would include individuals of all ages. SECTION 5. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS Non-binding language that: Recognizes that the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases. Commends the non-profit and private sector psoriasis research communities for planning a multi-disciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions. Encourages the National Institutes of Health (NIH) to continue to work with the organizations and private sector stakeholders who convene the multi-disciplinary scientific meeting to discuss future directions of psoriasis and comorbid research. Suggests that the non-profit and private sector meeting conveners disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from NIH and other relevant federal agencies. Encourages the Secretary of the Department of Health and Human Services (HHS), acting through the Director of the NIH, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases (NIAMS) and other NIH institutes and centers, to utilize the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research and to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged.

H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SECTION 4. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION Authorizes the Centers for Disease Control and Prevention (CDC) to undertake psoriasis and psoriatic arthritis data collection efforts including: incorporating questions into existing public health surveys, questionnaires and other databases to collect information regarding prevalence in the United States, age of onset, health-related quality of life, health care utilization, burden of disease (employment, work, etc.), direct and indirect costs, health disparities (age, gender, racial, ethnic), comorbidities and natural history of disease. These efforts may include the consideration and development of a patient registry, which would include individuals of all ages. SECTION 5. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS Non-binding language that: Recognizes that the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases. Commends the non-profit and private sector psoriasis research communities for planning a multi-disciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions. Encourages the National Institutes of Health (NIH) to continue to work with the organizations and private sector stakeholders who convene the multi-disciplinary scientific meeting to discuss future directions of psoriasis and comorbid research. Suggests that the non-profit and private sector meeting conveners disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from NIH and other relevant federal agencies. Encourages the Secretary of the Department of Health and Human Services (HHS), acting through the Director of the NIH, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases (NIAMS) and other NIH institutes and centers, to utilize the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research and to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged

H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SECTION 4. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION Authorizes the Centers for Disease Control and Prevention (CDC) to undertake psoriasis and psoriatic arthritis data collection efforts including: incorporating questions into existing public health surveys, questionnaires and other databases to collect information regarding prevalence in the United States, age of onset, health-related quality of life, health care utilization, burden of disease (employment, work, etc.), direct and indirect costs, health disparities (age, gender, racial, ethnic), comorbidities and natural history of disease. These efforts may include the consideration and development of a patient registry, which would include individuals of all ages. SECTION 5. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS Non-binding language that: Recognizes that the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases. Commends the non-profit and private sector psoriasis research communities for planning a multi-disciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions. Encourages the National Institutes of Health (NIH) to continue to work with the organizations and private sector stakeholders who convene the multi-disciplinary scientific meeting to discuss future directions of psoriasis and comorbid research. Suggests that the non-profit and private sector meeting conveners disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from NIH and other relevant federal agencies. Encourages the Secretary of the Department of Health and Human Services (HHS), acting through the Director of the NIH, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases (NIAMS) and other NIH institutes and centers, to utilize the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research and to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged

H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SECTION 4. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION Authorizes the Centers for Disease Control and Prevention (CDC) to undertake psoriasis and psoriatic arthritis data collection efforts including: incorporating questions into existing public health surveys, questionnaires and other databases to collect information regarding prevalence in the United States, age of onset, health-related quality of life, health care utilization, burden of disease (employment, work, etc.), direct and indirect costs, health disparities (age, gender, racial, ethnic), comorbidities and natural history of disease. These efforts may include the consideration and development of a patient registry, which would include individuals of all ages. SECTION 5. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS Non-binding language that: Recognizes that the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases. Commends the non-profit and private sector psoriasis research communities for planning a multi-disciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions. Encourages the National Institutes of Health (NIH) to continue to work with the organizations and private sector stakeholders who convene the multi-disciplinary scientific meeting to discuss future directions of psoriasis and comorbid research. Suggests that the non-profit and private sector meeting conveners disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from NIH and other relevant federal agencies. Encourages the Secretary of the Department of Health and Human Services (HHS), acting through the Director of the NIH, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases (NIAMS) and other NIH institutes and centers, to utilize the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research and to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged.

Access to care for people with psoriasis and psoriatic arthritis H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011

H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SECTION 4. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION Authorizes the Centers for Disease Control and Prevention (CDC) to undertake psoriasis and psoriatic arthritis data collection efforts including: incorporating questions into existing public health surveys, questionnaires and other databases to collect information regarding prevalence in the United States, age of onset, health-related quality of life, health care utilization, burden of disease (employment, work, etc.), direct and indirect costs, health disparities (age, gender, racial, ethnic), comorbidities and natural history of disease. These efforts may include the consideration and development of a patient registry, which would include individuals of all ages. SECTION 5. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS Non-binding language that: Recognizes that the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases. Commends the non-profit and private sector psoriasis research communities for planning a multi-disciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions. Encourages the National Institutes of Health (NIH) to continue to work with the organizations and private sector stakeholders who convene the multi-disciplinary scientific meeting to discuss future directions of psoriasis and comorbid research. Suggests that the non-profit and private sector meeting conveners disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from NIH and other relevant federal agencies. Encourages the Secretary of the Department of Health and Human Services (HHS), acting through the Director of the NIH, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases (NIAMS) and other NIH institutes and centers, to utilize the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research and to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged.

Access to care for people with psoriasis and psoriatic arthritis H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011

H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SEC. 3. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION. (a) In General- The Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention, is authorized to undertake psoriasis and psoriatic arthritis data collection efforts, including incorporating questions into public health surveys, questionnaires, and other databases in existence as of the date of the enactment of this Act to collect information, with respect to psoriasis and psoriatic arthritis, regarding-- (1) the prevalence of psoriasis and psoriatic arthritis in the United States; (2) the age of onset; (3) health-related quality of life; (4) health care utilization; (5) burden of such disease (such as with respect to employment); (6) direct and indirect costs; (7) health disparities, including with respect to age, gender, race, and ethnicity; and (8) comorbidities and the natural history of such disease. Such data collection efforts may include the consideration and development of a patient registry, which would include individuals of all ages. (b) Authorization of Appropriations- To carry out subsection (a), there are authorized to be appropriated $1,500,000 for each of fiscal years 2012 through 2017. SEC. 4. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS. It is the sense of the Congress that-- (1) the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases; (2) the nonprofit and private sector psoriasis research communities are to be commended for planning a multidisciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions; (3) the National Institutes of Health is encouraged to continue to work with the organizations and private sector stakeholders who convene the multidisciplinary scientific meeting to discuss future directions of psoriasis and comorbid research; (4) the nonprofit and private sector meeting conveners should disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from the National Institutes of Health and other relevant Federal agencies; and (5) utilizing the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research, the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases and other institutes and centers of the National Institutes of Health, is encouraged to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged.

Access to care for people with psoriasis and psoriatic arthritis H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011

Access to care for people with psoriasis and psoriatic arthritis H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011

H.R. 930: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 S. 571: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 SEC. 4. EXPANSION OF BIOMEDICAL RESEARCH. (a) In General- The Secretary of Health and Human Services (in this Act referred to as the `Secretary'), acting through the Director of the National Institutes of Health, shall continue to expand and intensify research and related activities of the Institutes with respect to psoriasis and psoriatic arthritis. (b) Research by National Institute of Arthritis and Musculoskeletal and Skin Diseases- (1) IN GENERAL- The directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall continue to conduct and support research to expand understanding of the causes of, and to find a cure for, psoriasis and psoriatic arthritis, including the following: (A) Basic research to discover the pathogenesis and pathophysiology of the disease. (B) Expansion of molecular biology and immunology studies, including additional animal models. (C) Global association mapping with single nucleotide polymorphisms. (D) Identification of environmental triggers and autoantigens in psoriasis . (E) Elucidation of specific immunologic cells and their products involved. (F) Pharmacogenetic studies to understand the molecular basis for varying patient response to treatment. (G) Identification of genetic markers of psoriatic arthritis susceptibility. (H) Research to increase understanding of joint inflammation and destruction in psoriatic arthritis. (I) Investigator-initiated clinical research for the development and evaluation of new treatments, including new biological agents. (J) Research to develop enhanced diagnostic tests that allow for earlier diagnosis of psoriasis and improved outcomes. (K) Research to increase understanding of the epidemiology and pathophysiology of co-morbidities associated with psoriasis , including shared molecular pathways. (2) COORDINATION WITH OTHER INSTITUTES- In carrying out paragraph (1), the directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall coordinate the activities of such Institutes with the activities of other national research institutes and other agencies and offices of the National Institutes of Health relating to psoriasis or psoriatic arthritis. SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 6. NATIONAL SUMMIT. (a) In General- Not later than one year after the date of the enactment of this Act, the Secretary is encouraged to convene a summit on the Federal Government's current and future efforts, and the initiatives necessary to fill any gaps, with respect to the conduct or support of psoriasis and psoriatic arthritis research, treatment, education, quality-of-life, and data collection activities. The summit should also address psoriasis and psoriatic arthritis related co-morbidities and should include researchers, public health professionals, representatives of voluntary health agencies and patient advocacy organizations, representatives of academic institutions, representatives from the pharmaceutical and medical research industry, and Federal and State policymakers, including representatives of the Agency for Healthcare Research and Quality, the Centers for Disease Control and Prevention, the Food and Drug Administration, and the National Institutes of Health. (b) Focus- The summit convened under this section should focus on-- (1) a broad range of research activities relating to biomedical, epidemiological, psychosocial, and rehabilitative issues; (2) clinical research for the development and evaluation of new treatments, including new biological agents; (3) translational research; (4) information and education programs for health care professionals and the public; (5) priorities among the programs and activities of the various Federal agencies involved in psoriasis and psoriatic arthritis and related co-morbidities; and (6) challenges, opportunities, and recommendations for scientists, clinicians, patients, and voluntary organizations. (c) Report to Congress- Not later than 180 days after the first day of the summit convened under this section, the Secretary shall submit to the Congress and make publicly available a report that includes a description of-- (1) the proceedings at the summit; and (2) recommendations related to the research, treatment, education, and quality-of-life activities conducted or supported by the Federal Government with respect to psoriasis and psoriatic arthritis, including psoriasis and psoriatic arthritis related co-morbidities

Access to care for people with psoriasis and psoriatic arthritis H.R. 930 and S. 571, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009 SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 7. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE. (a) In General- The Secretary shall enter into an agreement with the Institute of Medicine to conduct a study on the following: (1) The extent to which public and private insurers cover prescription medications and other treatments for psoriasis and psoriatic arthritis. (2) The payment structures, such as deductibles and co-payments, and the amounts and duration of coverage under health plans and their adequacy to cover the costs of providing ongoing care to, and ensure access for, patients with psoriasis and psoriatic arthritis. (3) Health plan and insurer coverage policies and practices, including lifetime caps, and their impact on the access of such patients to the best regimen and most appropriate care for their particular disease state. (b) Report- The agreement entered into under subsection (a) shall provide for the Institute of Medicine to submit to the Secretary and the Congress, not later than 18 months after the date of the enactment of this Act, a report containing a description of-- (1) the results of the study conducted under this section; and (2) the conclusions and recommendations of the Institutes of Medicine regarding each of the issues described in paragraphs (1) through (3) of subsection (a).

Access to care for people with psoriasis and psoriatic arthritis H.R. 930 and S. 571, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009 SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 7. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE. (a) In General- The Secretary shall enter into an agreement with the Institute of Medicine to conduct a study on the following: (1) The extent to which public and private insurers cover prescription medications and other treatments for psoriasis and psoriatic arthritis. (2) The payment structures, such as deductibles and co-payments, and the amounts and duration of coverage under health plans and their adequacy to cover the costs of providing ongoing care to, and ensure access for, patients with psoriasis and psoriatic arthritis. (3) Health plan and insurer coverage policies and practices, including lifetime caps, and their impact on the access of such patients to the best regimen and most appropriate care for their particular disease state. (b) Report- The agreement entered into under subsection (a) shall provide for the Institute of Medicine to submit to the Secretary and the Congress, not later than 18 months after the date of the enactment of this Act, a report containing a description of-- (1) the results of the study conducted under this section; and (2) the conclusions and recommendations of the Institutes of Medicine regarding each of the issues described in paragraphs (1) through (3) of subsection (a).

H.R. 930: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 S. 571: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 SEC. 4. EXPANSION OF BIOMEDICAL RESEARCH. (a) In General- The Secretary of Health and Human Services (in this Act referred to as the `Secretary'), acting through the Director of the National Institutes of Health, shall continue to expand and intensify research and related activities of the Institutes with respect to psoriasis and psoriatic arthritis. (b) Research by National Institute of Arthritis and Musculoskeletal and Skin Diseases- (1) IN GENERAL- The directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall continue to conduct and support research to expand understanding of the causes of, and to find a cure for, psoriasis and psoriatic arthritis, including the following: (A) Basic research to discover the pathogenesis and pathophysiology of the disease. (B) Expansion of molecular biology and immunology studies, including additional animal models. (C) Global association mapping with single nucleotide polymorphisms. (D) Identification of environmental triggers and autoantigens in psoriasis . (E) Elucidation of specific immunologic cells and their products involved. (F) Pharmacogenetic studies to understand the molecular basis for varying patient response to treatment. (G) Identification of genetic markers of psoriatic arthritis susceptibility. (H) Research to increase understanding of joint inflammation and destruction in psoriatic arthritis. (I) Investigator-initiated clinical research for the development and evaluation of new treatments, including new biological agents. (J) Research to develop enhanced diagnostic tests that allow for earlier diagnosis of psoriasis and improved outcomes. (K) Research to increase understanding of the epidemiology and pathophysiology of co-morbidities associated with psoriasis , including shared molecular pathways. (2) COORDINATION WITH OTHER INSTITUTES- In carrying out paragraph (1), the directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall coordinate the activities of such Institutes with the activities of other national research institutes and other agencies and offices of the National Institutes of Health relating to psoriasis or psoriatic arthritis. SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 6. NATIONAL SUMMIT. (a) In General- Not later than one year after the date of the enactment of this Act, the Secretary is encouraged to convene a summit on the Federal Government's current and future efforts, and the initiatives necessary to fill any gaps, with respect to the conduct or support of psoriasis and psoriatic arthritis research, treatment, education, quality-of-life, and data collection activities. The summit should also address psoriasis and psoriatic arthritis related co-morbidities and should include researchers, public health professionals, representatives of voluntary health agencies and patient advocacy organizations, representatives of academic institutions, representatives from the pharmaceutical and medical research industry, and Federal and State policymakers, including representatives of the Agency for Healthcare Research and Quality, the Centers for Disease Control and Prevention, the Food and Drug Administration, and the National Institutes of Health. (b) Focus- The summit convened under this section should focus on-- (1) a broad range of research activities relating to biomedical, epidemiological, psychosocial, and rehabilitative issues; (2) clinical research for the development and evaluation of new treatments, including new biological agents; (3) translational research; (4) information and education programs for health care professionals and the public; (5) priorities among the programs and activities of the various Federal agencies involved in psoriasis and psoriatic arthritis and related co-morbidities; and (6) challenges, opportunities, and recommendations for scientists, clinicians, patients, and voluntary organizations. (c) Report to Congress- Not later than 180 days after the first day of the summit convened under this section, the Secretary shall submit to the Congress and make publicly available a report that includes a description of-- (1) the proceedings at the summit; and (2) recommendations related to the research, treatment, education, and quality-of-life activities conducted or supported by the Federal Government with respect to psoriasis and psoriatic arthritis, including psoriasis and psoriatic arthritis related co-morbidities.

Access to care for people with psoriasis and psoriatic arthritis H.R. 930 and S. 571, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009 SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 7. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE. (a) In General- The Secretary shall enter into an agreement with the Institute of Medicine to conduct a study on the following: (1) The extent to which public and private insurers cover prescription medications and other treatments for psoriasis and psoriatic arthritis. (2) The payment structures, such as deductibles and co-payments, and the amounts and duration of coverage under health plans and their adequacy to cover the costs of providing ongoing care to, and ensure access for, patients with psoriasis and psoriatic arthritis. (3) Health plan and insurer coverage policies and practices, including lifetime caps, and their impact on the access of such patients to the best regimen and most appropriate care for their particular disease state. (b) Report- The agreement entered into under subsection (a) shall provide for the Institute of Medicine to submit to the Secretary and the Congress, not later than 18 months after the date of the enactment of this Act, a report containing a description of-- (1) the results of the study conducted under this section; and (2) the conclusions and recommendations of the Institutes of Medicine regarding each of the issues described in paragraphs (1) through (3) of subsection (a).

H.R. 930: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 S. 571: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 SEC. 4. EXPANSION OF BIOMEDICAL RESEARCH. (a) In General- The Secretary of Health and Human Services (in this Act referred to as the `Secretary'), acting through the Director of the National Institutes of Health, shall continue to expand and intensify research and related activities of the Institutes with respect to psoriasis and psoriatic arthritis. (b) Research by National Institute of Arthritis and Musculoskeletal and Skin Diseases- (1) IN GENERAL- The directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall continue to conduct and support research to expand understanding of the causes of, and to find a cure for, psoriasis and psoriatic arthritis, including the following: (A) Basic research to discover the pathogenesis and pathophysiology of the disease. (B) Expansion of molecular biology and immunology studies, including additional animal models. (C) Global association mapping with single nucleotide polymorphisms. (D) Identification of environmental triggers and autoantigens in psoriasis . (E) Elucidation of specific immunologic cells and their products involved. (F) Pharmacogenetic studies to understand the molecular basis for varying patient response to treatment. (G) Identification of genetic markers of psoriatic arthritis susceptibility. (H) Research to increase understanding of joint inflammation and destruction in psoriatic arthritis. (I) Investigator-initiated clinical research for the development and evaluation of new treatments, including new biological agents. (J) Research to develop enhanced diagnostic tests that allow for earlier diagnosis of psoriasis and improved outcomes. (K) Research to increase understanding of the epidemiology and pathophysiology of co-morbidities associated with psoriasis , including shared molecular pathways. (2) COORDINATION WITH OTHER INSTITUTES- In carrying out paragraph (1), the directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall coordinate the activities of such Institutes with the activities of other national research institutes and other agencies and offices of the National Institutes of Health relating to psoriasis or psoriatic arthritis. SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 6. NATIONAL SUMMIT. (a) In General- Not later than one year after the date of the enactment of this Act, the Secretary is encouraged to convene a summit on the Federal Government's current and future efforts, and the initiatives necessary to fill any gaps, with respect to the conduct or support of psoriasis and psoriatic arthritis research, treatment, education, quality-of-life, and data collection activities. The summit should also address psoriasis and psoriatic arthritis related co-morbidities and should include researchers, public health professionals, representatives of voluntary health agencies and patient advocacy organizations, representatives of academic institutions, representatives from the pharmaceutical and medical research industry, and Federal and State policymakers, including representatives of the Agency for Healthcare Research and Quality, the Centers for Disease Control and Prevention, the Food and Drug Administration, and the National Institutes of Health. (b) Focus- The summit convened under this section should focus on-- (1) a broad range of research activities relating to biomedical, epidemiological, psychosocial, and rehabilitative issues; (2) clinical research for the development and evaluation of new treatments, including new biological agents; (3) translational research; (4) information and education programs for health care professionals and the public; (5) priorities among the programs and activities of the various Federal agencies involved in psoriasis and psoriatic arthritis and related co-morbidities; and (6) challenges, opportunities, and recommendations for scientists, clinicians, patients, and voluntary organizations. (c) Report to Congress- Not later than 180 days after the first day of the summit convened under this section, the Secretary shall submit to the Congress and make publicly available a report that includes a description of-- (1) the proceedings at the summit; and (2) recommendations related to the research, treatment, education, and quality-of-life activities conducted or supported by the Federal Government with respect to psoriasis and psoriatic arthritis, including psoriasis and psoriatic arthritis related co-morbidities.

Access to care for people with psoriasis and psoriatic arthritis H.R. 930 and S. 571, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009 SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 7. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE. (a) In General- The Secretary shall enter into an agreement with the Institute of Medicine to conduct a study on the following: (1) The extent to which public and private insurers cover prescription medications and other treatments for psoriasis and psoriatic arthritis. (2) The payment structures, such as deductibles and co-payments, and the amounts and duration of coverage under health plans and their adequacy to cover the costs of providing ongoing care to, and ensure access for, patients with psoriasis and psoriatic arthritis. (3) Health plan and insurer coverage policies and practices, including lifetime caps, and their impact on the access of such patients to the best regimen and most appropriate care for their particular disease state. (b) Report- The agreement entered into under subsection (a) shall provide for the Institute of Medicine to submit to the Secretary and the Congress, not later than 18 months after the date of the enactment of this Act, a report containing a description of-- (1) the results of the study conducted under this section; and (2) the conclusions and recommendations of the Institutes of Medicine regarding each of the issues described in paragraphs (1) through (3) of subsection (a).

H.R. 930: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 S. 571: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 SEC. 4. EXPANSION OF BIOMEDICAL RESEARCH. (a) In General- The Secretary of Health and Human Services (in this Act referred to as the `Secretary'), acting through the Director of the National Institutes of Health, shall continue to expand and intensify research and related activities of the Institutes with respect to psoriasis and psoriatic arthritis. (b) Research by National Institute of Arthritis and Musculoskeletal and Skin Diseases- (1) IN GENERAL- The directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall continue to conduct and support research to expand understanding of the causes of, and to find a cure for, psoriasis and psoriatic arthritis, including the following: (A) Basic research to discover the pathogenesis and pathophysiology of the disease. (B) Expansion of molecular biology and immunology studies, including additional animal models. (C) Global association mapping with single nucleotide polymorphisms. (D) Identification of environmental triggers and autoantigens in psoriasis . (E) Elucidation of specific immunologic cells and their products involved. (F) Pharmacogenetic studies to understand the molecular basis for varying patient response to treatment. (G) Identification of genetic markers of psoriatic arthritis susceptibility. (H) Research to increase understanding of joint inflammation and destruction in psoriatic arthritis. (I) Investigator-initiated clinical research for the development and evaluation of new treatments, including new biological agents. (J) Research to develop enhanced diagnostic tests that allow for earlier diagnosis of psoriasis and improved outcomes. (K) Research to increase understanding of the epidemiology and pathophysiology of co-morbidities associated with psoriasis , including shared molecular pathways. (2) COORDINATION WITH OTHER INSTITUTES- In carrying out paragraph (1), the directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall coordinate the activities of such Institutes with the activities of other national research institutes and other agencies and offices of the National Institutes of Health relating to psoriasis or psoriatic arthritis. SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 6. NATIONAL SUMMIT. (a) In General- Not later than one year after the date of the enactment of this Act, the Secretary is encouraged to convene a summit on the Federal Government's current and future efforts, and the initiatives necessary to fill any gaps, with respect to the conduct or support of psoriasis and psoriatic arthritis research, treatment, education, quality-of-life, and data collection activities. The summit should also address psoriasis and psoriatic arthritis related co-morbidities and should include researchers, public health professionals, representatives of voluntary health agencies and patient advocacy organizations, representatives of academic institutions, representatives from the pharmaceutical and medical research industry, and Federal and State policymakers, including representatives of the Agency for Healthcare Research and Quality, the Centers for Disease Control and Prevention, the Food and Drug Administration, and the National Institutes of Health. (b) Focus- The summit convened under this section should focus on-- (1) a broad range of research activities relating to biomedical, epidemiological, psychosocial, and rehabilitative issues; (2) clinical research for the development and evaluation of new treatments, including new biological agents; (3) translational research; (4) information and education programs for health care professionals and the public; (5) priorities among the programs and activities of the various Federal agencies involved in psoriasis and psoriatic arthritis and related co-morbidities; and (6) challenges, opportunities, and recommendations for scientists, clinicians, patients, and voluntary organizations. (c) Report to Congress- Not later than 180 days after the first day of the summit convened under this section, the Secretary shall submit to the Congress and make publicly available a report that includes a description of-- (1) the proceedings at the summit; and (2) recommendations related to the research, treatment, education, and quality-of-life activities conducted or supported by the Federal Government with respect to psoriasis and psoriatic arthritis, including psoriasis and psoriatic arthritis related co-morbidities.

H.R. 930: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 S. 571: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 SEC. 4. EXPANSION OF BIOMEDICAL RESEARCH. (a) In General- The Secretary of Health and Human Services (in this Act referred to as the `Secretary'), acting through the Director of the National Institutes of Health, shall continue to expand and intensify research and related activities of the Institutes with respect to psoriasis and psoriatic arthritis. (b) Research by National Institute of Arthritis and Musculoskeletal and Skin Diseases- (1) IN GENERAL- The directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall continue to conduct and support research to expand understanding of the causes of, and to find a cure for, psoriasis and psoriatic arthritis, including the following: (A) Basic research to discover the pathogenesis and pathophysiology of the disease. (B) Expansion of molecular biology and immunology studies, including additional animal models. (C) Global association mapping with single nucleotide polymorphisms. (D) Identification of environmental triggers and autoantigens in psoriasis . (E) Elucidation of specific immunologic cells and their products involved. (F) Pharmacogenetic studies to understand the molecular basis for varying patient response to treatment. (G) Identification of genetic markers of psoriatic arthritis susceptibility. (H) Research to increase understanding of joint inflammation and destruction in psoriatic arthritis. (I) Investigator-initiated clinical research for the development and evaluation of new treatments, including new biological agents. (J) Research to develop enhanced diagnostic tests that allow for earlier diagnosis of psoriasis and improved outcomes. (K) Research to increase understanding of the epidemiology and pathophysiology of co-morbidities associated with psoriasis , including shared molecular pathways. (2) COORDINATION WITH OTHER INSTITUTES- In carrying out paragraph (1), the directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall coordinate the activities of such Institutes with the activities of other national research institutes and other agencies and offices of the National Institutes of Health relating to psoriasis or psoriatic arthritis. SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 6. NATIONAL SUMMIT. (a) In General- Not later than one year after the date of the enactment of this Act, the Secretary is encouraged to convene a summit on the Federal Government's current and future efforts, and the initiatives necessary to fill any gaps, with respect to the conduct or support of psoriasis and psoriatic arthritis research, treatment, education, quality-of-life, and data collection activities. The summit should also address psoriasis and psoriatic arthritis related co-morbidities and should include researchers, public health professionals, representatives of voluntary health agencies and patient advocacy organizations, representatives of academic institutions, representatives from the pharmaceutical and medical research industry, and Federal and State policymakers, including representatives of the Agency for Healthcare Research and Quality, the Centers for Disease Control and Prevention, the Food and Drug Administration, and the National Institutes of Health. (b) Focus- The summit convened under this section should focus on-- (1) a broad range of research activities relating to biomedical, epidemiological, psychosocial, and rehabilitative issues; (2) clinical research for the development and evaluation of new treatments, including new biological agents; (3) translational research; (4) information and education programs for health care professionals and the public; (5) priorities among the programs and activities of the various Federal agencies involved in psoriasis and psoriatic arthritis and related co-morbidities; and (6) challenges, opportunities, and recommendations for scientists, clinicians, patients, and voluntary organizations. (c) Report to Congress- Not later than 180 days after the first day of the summit convened under this section, the Secretary shall submit to the Congress and make publicly available a report that includes a description of-- (1) the proceedings at the summit; and (2) recommendations related to the research, treatment, education, and quality-of-life activities conducted or supported by the Federal Government with respect to psoriasis and psoriatic arthritis, including psoriasis and psoriatic arthritis related co-morbidities.

H.R. 930: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 S. 571: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 SEC. 4. EXPANSION OF BIOMEDICAL RESEARCH. (a) In General- The Secretary of Health and Human Services (in this Act referred to as the `Secretary'), acting through the Director of the National Institutes of Health, shall continue to expand and intensify research and related activities of the Institutes with respect to psoriasis and psoriatic arthritis. (b) Research by National Institute of Arthritis and Musculoskeletal and Skin Diseases- (1) IN GENERAL- The directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall continue to conduct and support research to expand understanding of the causes of, and to find a cure for, psoriasis and psoriatic arthritis, including the following: (A) Basic research to discover the pathogenesis and pathophysiology of the disease. (B) Expansion of molecular biology and immunology studies, including additional animal models. (C) Global association mapping with single nucleotide polymorphisms. (D) Identification of environmental triggers and autoantigens in psoriasis . (E) Elucidation of specific immunologic cells and their products involved. (F) Pharmacogenetic studies to understand the molecular basis for varying patient response to treatment. (G) Identification of genetic markers of psoriatic arthritis susceptibility. (H) Research to increase understanding of joint inflammation and destruction in psoriatic arthritis. (I) Investigator-initiated clinical research for the development and evaluation of new treatments, including new biological agents. (J) Research to develop enhanced diagnostic tests that allow for earlier diagnosis of psoriasis and improved outcomes. (K) Research to increase understanding of the epidemiology and pathophysiology of co-morbidities associated with psoriasis , including shared molecular pathways. (2) COORDINATION WITH OTHER INSTITUTES- In carrying out paragraph (1), the directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall coordinate the activities of such Institutes with the activities of other national research institutes and other agencies and offices of the National Institutes of Health relating to psoriasis or psoriatic arthritis. SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 6. NATIONAL SUMMIT. (a) In General- Not later than one year after the date of the enactment of this Act, the Secretary is encouraged to convene a summit on the Federal Government's current and future efforts, and the initiatives necessary to fill any gaps, with respect to the conduct or support of psoriasis and psoriatic arthritis research, treatment, education, quality-of-life, and data collection activities. The summit should also address psoriasis and psoriatic arthritis related co-morbidities and should include researchers, public health professionals, representatives of voluntary health agencies and patient advocacy organizations, representatives of academic institutions, representatives from the pharmaceutical and medical research industry, and Federal and State policymakers, including representatives of the Agency for Healthcare Research and Quality, the Centers for Disease Control and Prevention, the Food and Drug Administration, and the National Institutes of Health. (b) Focus- The summit convened under this section should focus on-- (1) a broad range of research activities relating to biomedical, epidemiological, psychosocial, and rehabilitative issues; (2) clinical research for the development and evaluation of new treatments, including new biological agents; (3) translational research; (4) information and education programs for health care professionals and the public; (5) priorities among the programs and activities of the various Federal agencies involved in psoriasis and psoriatic arthritis and related co-morbidities; and (6) challenges, opportunities, and recommendations for scientists, clinicians, patients, and voluntary organizations. (c) Report to Congress- Not later than 180 days after the first day of the summit convened under this section, the Secretary shall submit to the Congress and make publicly available a report that includes a description of-- (1) the proceedings at the summit; and (2) recommendations related to the research, treatment, education, and quality-of-life activities conducted or supported by the Federal Government with respect to psoriasis and psoriatic arthritis, including psoriasis and psoriatic arthritis related co-morbidities

Access to care for people with psoriasis and psoriatic arthritis H.R. 930 and S. 571, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009 SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 7. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE. (a) In General- The Secretary shall enter into an agreement with the Institute of Medicine to conduct a study on the following: (1) The extent to which public and private insurers cover prescription medications and other treatments for psoriasis and psoriatic arthritis. (2) The payment structures, such as deductibles and co-payments, and the amounts and duration of coverage under health plans and their adequacy to cover the costs of providing ongoing care to, and ensure access for, patients with psoriasis and psoriatic arthritis. (3) Health plan and insurer coverage policies and practices, including lifetime caps, and their impact on the access of such patients to the best regimen and most appropriate care for their particular disease state. (b) Report- The agreement entered into under subsection (a) shall provide for the Institute of Medicine to submit to the Secretary and the Congress, not later than 18 months after the date of the enactment of this Act, a report containing a description of-- (1) the results of the study conducted under this section; and (2) the conclusions and recommendations of the Institutes of Medicine regarding each of the issues described in paragraphs (1) through (3) of subsection (a).

Access to care for people with psoriasis and psoriatic arthritis H.R. 930 and S. 571, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009 SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 7. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE. (a) In General- The Secretary shall enter into an agreement with the Institute of Medicine to conduct a study on the following: (1) The extent to which public and private insurers cover prescription medications and other treatments for psoriasis and psoriatic arthritis. (2) The payment structures, such as deductibles and co-payments, and the amounts and duration of coverage under health plans and their adequacy to cover the costs of providing ongoing care to, and ensure access for, patients with psoriasis and psoriatic arthritis. (3) Health plan and insurer coverage policies and practices, including lifetime caps, and their impact on the access of such patients to the best regimen and most appropriate care for their particular disease state. (b) Report- The agreement entered into under subsection (a) shall provide for the Institute of Medicine to submit to the Secretary and the Congress, not later than 18 months after the date of the enactment of this Act, a report containing a description of-- (1) the results of the study conducted under this section; and (2) the conclusions and recommendations of the Institutes of Medicine regarding each of the issues described in paragraphs (1) through (3) of subsection (a).

Access to care for people with psoriasis and psoriatic arthritis H.R. 930 and S. 571, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009 SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 7. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE. (a) In General- The Secretary shall enter into an agreement with the Institute of Medicine to conduct a study on the following: (1) The extent to which public and private insurers cover prescription medications and other treatments for psoriasis and psoriatic arthritis. (2) The payment structures, such as deductibles and co-payments, and the amounts and duration of coverage under health plans and their adequacy to cover the costs of providing ongoing care to, and ensure access for, patients with psoriasis and psoriatic arthritis. (3) Health plan and insurer coverage policies and practices, including lifetime caps, and their impact on the access of such patients to the best regimen and most appropriate care for their particular disease state. (b) Report- The agreement entered into under subsection (a) shall provide for the Institute of Medicine to submit to the Secretary and the Congress, not later than 18 months after the date of the enactment of this Act, a report containing a description of-- (1) the results of the study conducted under this section; and (2) the conclusions and recommendations of the Institutes of Medicine regarding each of the issues described in paragraphs (1) through (3) of subsection (a).

H.R. 930: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 S. 571: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 SEC. 4. EXPANSION OF BIOMEDICAL RESEARCH. (a) In General- The Secretary of Health and Human Services (in this Act referred to as the `Secretary'), acting through the Director of the National Institutes of Health, shall continue to expand and intensify research and related activities of the Institutes with respect to psoriasis and psoriatic arthritis. (b) Research by National Institute of Arthritis and Musculoskeletal and Skin Diseases- (1) IN GENERAL- The directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall continue to conduct and support research to expand understanding of the causes of, and to find a cure for, psoriasis and psoriatic arthritis, including the following: (A) Basic research to discover the pathogenesis and pathophysiology of the disease. (B) Expansion of molecular biology and immunology studies, including additional animal models. (C) Global association mapping with single nucleotide polymorphisms. (D) Identification of environmental triggers and autoantigens in psoriasis . (E) Elucidation of specific immunologic cells and their products involved. (F) Pharmacogenetic studies to understand the molecular basis for varying patient response to treatment. (G) Identification of genetic markers of psoriatic arthritis susceptibility. (H) Research to increase understanding of joint inflammation and destruction in psoriatic arthritis. (I) Investigator-initiated clinical research for the development and evaluation of new treatments, including new biological agents. (J) Research to develop enhanced diagnostic tests that allow for earlier diagnosis of psoriasis and improved outcomes. (K) Research to increase understanding of the epidemiology and pathophysiology of co-morbidities associated with psoriasis , including shared molecular pathways. (2) COORDINATION WITH OTHER INSTITUTES- In carrying out paragraph (1), the directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall coordinate the activities of such Institutes with the activities of other national research institutes and other agencies and offices of the National Institutes of Health relating to psoriasis or psoriatic arthritis. SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 6. NATIONAL SUMMIT. (a) In General- Not later than one year after the date of the enactment of this Act, the Secretary is encouraged to convene a summit on the Federal Government's current and future efforts, and the initiatives necessary to fill any gaps, with respect to the conduct or support of psoriasis and psoriatic arthritis research, treatment, education, quality-of-life, and data collection activities. The summit should also address psoriasis and psoriatic arthritis related co-morbidities and should include researchers, public health professionals, representatives of voluntary health agencies and patient advocacy organizations, representatives of academic institutions, representatives from the pharmaceutical and medical research industry, and Federal and State policymakers, including representatives of the Agency for Healthcare Research and Quality, the Centers for Disease Control and Prevention, the Food and Drug Administration, and the National Institutes of Health. (b) Focus- The summit convened under this section should focus on-- (1) a broad range of research activities relating to biomedical, epidemiological, psychosocial, and rehabilitative issues; (2) clinical research for the development and evaluation of new treatments, including new biological agents; (3) translational research; (4) information and education programs for health care professionals and the public; (5) priorities among the programs and activities of the various Federal agencies involved in psoriasis and psoriatic arthritis and related co-morbidities; and (6) challenges, opportunities, and recommendations for scientists, clinicians, patients, and voluntary organizations. (c) Report to Congress- Not later than 180 days after the first day of the summit convened under this section, the Secretary shall submit to the Congress and make publicly available a report that includes a description of-- (1) the proceedings at the summit; and (2) recommendations related to the research, treatment, education, and quality-of-life activities conducted or supported by the Federal Government with respect to psoriasis and psoriatic arthritis, including psoriasis and psoriatic arthritis related co-morbidities.

Access to care for people with psoriasis and psoriatic arthritis H.R. 930 and S. 571, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009 SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 7. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE. (a) In General- The Secretary shall enter into an agreement with the Institute of Medicine to conduct a study on the following: (1) The extent to which public and private insurers cover prescription medications and other treatments for psoriasis and psoriatic arthritis. (2) The payment structures, such as deductibles and co-payments, and the amounts and duration of coverage under health plans and their adequacy to cover the costs of providing ongoing care to, and ensure access for, patients with psoriasis and psoriatic arthritis. (3) Health plan and insurer coverage policies and practices, including lifetime caps, and their impact on the access of such patients to the best regimen and most appropriate care for their particular disease state. (b) Report- The agreement entered into under subsection (a) shall provide for the Institute of Medicine to submit to the Secretary and the Congress, not later than 18 months after the date of the enactment of this Act, a report containing a description of-- (1) the results of the study conducted under this section; and (2) the conclusions and recommendations of the Institutes of Medicine regarding each of the issues described in paragraphs (1) through (3) of subsection (a).

H.R. 930: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 S. 571: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 SEC. 4. EXPANSION OF BIOMEDICAL RESEARCH. (a) In General- The Secretary of Health and Human Services (in this Act referred to as the `Secretary'), acting through the Director of the National Institutes of Health, shall continue to expand and intensify research and related activities of the Institutes with respect to psoriasis and psoriatic arthritis. (b) Research by National Institute of Arthritis and Musculoskeletal and Skin Diseases- (1) IN GENERAL- The directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall continue to conduct and support research to expand understanding of the causes of, and to find a cure for, psoriasis and psoriatic arthritis, including the following: (A) Basic research to discover the pathogenesis and pathophysiology of the disease. (B) Expansion of molecular biology and immunology studies, including additional animal models. (C) Global association mapping with single nucleotide polymorphisms. (D) Identification of environmental triggers and autoantigens in psoriasis . (E) Elucidation of specific immunologic cells and their products involved. (F) Pharmacogenetic studies to understand the molecular basis for varying patient response to treatment. (G) Identification of genetic markers of psoriatic arthritis susceptibility. (H) Research to increase understanding of joint inflammation and destruction in psoriatic arthritis. (I) Investigator-initiated clinical research for the development and evaluation of new treatments, including new biological agents. (J) Research to develop enhanced diagnostic tests that allow for earlier diagnosis of psoriasis and improved outcomes. (K) Research to increase understanding of the epidemiology and pathophysiology of co-morbidities associated with psoriasis , including shared molecular pathways. (2) COORDINATION WITH OTHER INSTITUTES- In carrying out paragraph (1), the directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall coordinate the activities of such Institutes with the activities of other national research institutes and other agencies and offices of the National Institutes of Health relating to psoriasis or psoriatic arthritis. SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 6. NATIONAL SUMMIT. (a) In General- Not later than one year after the date of the enactment of this Act, the Secretary is encouraged to convene a summit on the Federal Government's current and future efforts, and the initiatives necessary to fill any gaps, with respect to the conduct or support of psoriasis and psoriatic arthritis research, treatment, education, quality-of-life, and data collection activities. The summit should also address psoriasis and psoriatic arthritis related co-morbidities and should include researchers, public health professionals, representatives of voluntary health agencies and patient advocacy organizations, representatives of academic institutions, representatives from the pharmaceutical and medical research industry, and Federal and State policymakers, including representatives of the Agency for Healthcare Research and Quality, the Centers for Disease Control and Prevention, the Food and Drug Administration, and the National Institutes of Health. (b) Focus- The summit convened under this section should focus on-- (1) a broad range of research activities relating to biomedical, epidemiological, psychosocial, and rehabilitative issues; (2) clinical research for the development and evaluation of new treatments, including new biological agents; (3) translational research; (4) information and education programs for health care professionals and the public; (5) priorities among the programs and activities of the various Federal agencies involved in psoriasis and psoriatic arthritis and related co-morbidities; and (6) challenges, opportunities, and recommendations for scientists, clinicians, patients, and voluntary organizations. (c) Report to Congress- Not later than 180 days after the first day of the summit convened under this section, the Secretary shall submit to the Congress and make publicly available a report that includes a description of-- (1) the proceedings at the summit; and (2) recommendations related to the research, treatment, education, and quality-of-life activities conducted or supported by the Federal Government with respect to psoriasis and psoriatic arthritis, including psoriasis and psoriatic arthritis related co-morbidities.

H.R. 930, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009 S. 571, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009 SEC. 4. EXPANSION OF BIOMEDICAL RESEARCH. (a) In General- The Secretary of Health and Human Services (in this Act referred to as the `Secretary'), acting through the Director of the National Institutes of Health, shall continue to expand and intensify research and related activities of the Institutes with respect to psoriasis and psoriatic arthritis. (b) Research by National Institute of Arthritis and Musculoskeletal and Skin Diseases- (1) IN GENERAL- The directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall continue to conduct and support research to expand understanding of the causes of, and to find a cure for, psoriasis and psoriatic arthritis, including the following: (A) Basic research to discover the pathogenesis and pathophysiology of the disease. (B) Expansion of molecular biology and immunology studies, including additional animal models. (C) Global association mapping with single nucleotide polymorphisms. (D) Identification of environmental triggers and autoantigens in psoriasis. (E) Elucidation of specific immunologic cells and their products involved. (F) Pharmacogenetic studies to understand the molecular basis for varying patient response to treatment. (G) Identification of genetic markers of psoriatic arthritis susceptibility. (H) Research to increase understanding of joint inflammation and destruction in psoriatic arthritis. (I) Investigator-initiated clinical research for the development and evaluation of new treatments, including new biological agents. (J) Research to develop enhanced diagnostic tests that allow for earlier diagnosis of psoriasis and improved outcomes. (K) Research to increase understanding of the epidemiology and pathophysiology of co-morbidities associated with psoriasis, including shared molecular pathways. (2) COORDINATION WITH OTHER INSTITUTES- In carrying out paragraph (1), the directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall coordinate the activities of such Institutes with the activities of other national research institutes and other agencies and offices of the National Institutes of Health relating to psoriasis or psoriatic arthritis. SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 6. NATIONAL SUMMIT. (a) In General- Not later than one year after the date of the enactment of this Act, the Secretary is encouraged to convene a summit on the Federal Government's current and future efforts, and the initiatives necessary to fill any gaps, with respect to the conduct or support of psoriasis and psoriatic arthritis research, treatment, education, quality-of-life, and data collection activities. The summit should also address psoriasis and psoriatic arthritis related co-morbidities and should include researchers, public health professionals, representatives of voluntary health agencies and patient advocacy organizations, representatives of academic institutions, representatives from the pharmaceutical and medical research industry, and Federal and State policymakers, including representatives of the Agency for Healthcare Research and Quality, the Centers for Disease Control and Prevention, the Food and Drug Administration, and the National Institutes of Health. (b) Focus- The summit convened under this section should focus on-- (1) a broad range of research activities relating to biomedical, epidemiological, psychosocial, and rehabilitative issues; (2) clinical research for the development and evaluation of new treatments, including new biological agents; (3) translational research; (4) information and education programs for health care professionals and the public; (5) priorities among the programs and activities of the various Federal agencies involved in psoriasis and psoriatic arthritis and related co-morbidities; and (6) challenges, opportunities, and recommendations for scientists, clinicians, patients, and voluntary organizations. (c) Report to Congress- Not later than 180 days after the first day of the summit convened under this section, the Secretary shall submit to the Congress and make publicly available a report that includes a description of-- (1) the proceedings at the summit; and (2) recommendations related to the research, treatment, education, and quality-of-life activities conducted or supported by the Federal Government with respect to psoriasis and psoriatic arthritis, including psoriasis and psoriatic arthritis related co-morbidities.

Access to care for people with psoriasis and psoriatic arthritis H.R. 930 and S. 571, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009 SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 7. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE. (a) In General- The Secretary shall enter into an agreement with the Institute of Medicine to conduct a study on the following: (1) The extent to which public and private insurers cover prescription medications and other treatments for psoriasis and psoriatic arthritis. (2) The payment structures, such as deductibles and co-payments, and the amounts and duration of coverage under health plans and their adequacy to cover the costs of providing ongoing care to, and ensure access for, patients with psoriasis and psoriatic arthritis. (3) Health plan and insurer coverage policies and practices, including lifetime caps, and their impact on the access of such patients to the best regimen and most appropriate care for their particular disease state. (b) Report- The agreement entered into under subsection (a) shall provide for the Institute of Medicine to submit to the Secretary and the Congress, not later than 18 months after the date of the enactment of this Act, a report containing a description of-- (1) the results of the study conducted under this section; and (2) the conclusions and recommendations of the Institutes of Medicine regarding each of the issues described in paragraphs (1) through (3) of subsection (a).

Access to care for people with psoriasis and psoriatic arthritis H.R. 930 and S. 571, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009 SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 7. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE. (a) In General- The Secretary shall enter into an agreement with the Institute of Medicine to conduct a study on the following: (1) The extent to which public and private insurers cover prescription medications and other treatments for psoriasis and psoriatic arthritis. (2) The payment structures, such as deductibles and co-payments, and the amounts and duration of coverage under health plans and their adequacy to cover the costs of providing ongoing care to, and ensure access for, patients with psoriasis and psoriatic arthritis. (3) Health plan and insurer coverage policies and practices, including lifetime caps, and their impact on the access of such patients to the best regimen and most appropriate care for their particular disease state. (b) Report- The agreement entered into under subsection (a) shall provide for the Institute of Medicine to submit to the Secretary and the Congress, not later than 18 months after the date of the enactment of this Act, a report containing a description of-- (1) the results of the study conducted under this section; and (2) the conclusions and recommendations of the Institutes of Medicine regarding each of the issues described in paragraphs (1) through (3) of subsection (a).

Access to care for people with psoriasis and psoriatic arthritis H.R. 930 and S. 571, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009 H.R. 930 and S. 571, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009 SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 7. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE. (a) In General- The Secretary shall enter into an agreement with the Institute of Medicine to conduct a study on the following: (1) The extent to which public and private insurers cover prescription medications and other treatments for psoriasis and psoriatic arthritis. (2) The payment structures, such as deductibles and co-payments, and the amounts and duration of coverage under health plans and their adequacy to cover the costs of providing ongoing care to, and ensure access for, patients with psoriasis and psoriatic arthritis. (3) Health plan and insurer coverage policies and practices, including lifetime caps, and their impact on the access of such patients to the best regimen and most appropriate care for their particular disease state. (b) Report- The agreement entered into under subsection (a) shall provide for the Institute of Medicine to submit to the Secretary and the Congress, not later than 18 months after the date of the enactment of this Act, a report containing a description of-- (1) the results of the study conducted under this section; and (2) the conclusions and recommendations of the Institutes of Medicine regarding each of the issues described in paragraphs (1) through (3) of subsection (a).

H.R. 930, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009 S. 571, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009 SEC. 4. EXPANSION OF BIOMEDICAL RESEARCH. (a) In General- The Secretary of Health and Human Services (in this Act referred to as the `Secretary'), acting through the Director of the National Institutes of Health, shall continue to expand and intensify research and related activities of the Institutes with respect to psoriasis and psoriatic arthritis. (b) Research by National Institute of Arthritis and Musculoskeletal and Skin Diseases- (1) IN GENERAL- The directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall continue to conduct and support research to expand understanding of the causes of, and to find a cure for, psoriasis and psoriatic arthritis, including the following: (A) Basic research to discover the pathogenesis and pathophysiology of the disease. (B) Expansion of molecular biology and immunology studies, including additional animal models. (C) Global association mapping with single nucleotide polymorphisms. (D) Identification of environmental triggers and autoantigens in psoriasis . (E) Elucidation of specific immunologic cells and their products involved. (F) Pharmacogenetic studies to understand the molecular basis for varying patient response to treatment. (G) Identification of genetic markers of psoriatic arthritis susceptibility. (H) Research to increase understanding of joint inflammation and destruction in psoriatic arthritis. (I) Investigator-initiated clinical research for the development and evaluation of new treatments, including new biological agents. (J) Research to develop enhanced diagnostic tests that allow for earlier diagnosis of psoriasis and improved outcomes. (K) Research to increase understanding of the epidemiology and pathophysiology of co-morbidities associated with psoriasis , including shared molecular pathways. (2) COORDINATION WITH OTHER INSTITUTES- In carrying out paragraph (1), the directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall coordinate the activities of such Institutes with the activities of other national research institutes and other agencies and offices of the National Institutes of Health relating to psoriasis or psoriatic arthritis. SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 6. NATIONAL SUMMIT. (a) In General- Not later than one year after the date of the enactment of this Act, the Secretary is encouraged to convene a summit on the Federal Government's current and future efforts, and the initiatives necessary to fill any gaps, with respect to the conduct or support of psoriasis and psoriatic arthritis research, treatment, education, quality-of-life, and data collection activities. The summit should also address psoriasis and psoriatic arthritis related co-morbidities and should include researchers, public health professionals, representatives of voluntary health agencies and patient advocacy organizations, representatives of academic institutions, representatives from the pharmaceutical and medical research industry, and Federal and State policymakers, including representatives of the Agency for Healthcare Research and Quality, the Centers for Disease Control and Prevention, the Food and Drug Administration, and the National Institutes of Health. (b) Focus- The summit convened under this section should focus on-- (1) a broad range of research activities relating to biomedical, epidemiological, psychosocial, and rehabilitative issues; (2) clinical research for the development and evaluation of new treatments, including new biological agents; (3) translational research; (4) information and education programs for health care professionals and the public; (5) priorities among the programs and activities of the various Federal agencies involved in psoriasis and psoriatic arthritis and related co-morbidities; and (6) challenges, opportunities, and recommendations for scientists, clinicians, patients, and voluntary organizations. (c) Report to Congress- Not later than 180 days after the first day of the summit convened under this section, the Secretary shall submit to the Congress and make publicly available a report that includes a description of-- (1) the proceedings at the summit; and (2) recommendations related to the research, treatment, education, and quality-of-life activities conducted or supported by the Federal Government with respect to psoriasis and psoriatic arthritis, including psoriasis and psoriatic arthritis related co-morbidities.

H.R. 930: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 S. 571: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 SEC. 4. EXPANSION OF BIOMEDICAL RESEARCH. (a) In General- The Secretary of Health and Human Services (in this Act referred to as the `Secretary'), acting through the Director of the National Institutes of Health, shall continue to expand and intensify research and related activities of the Institutes with respect to psoriasis and psoriatic arthritis. (b) Research by National Institute of Arthritis and Musculoskeletal and Skin Diseases- (1) IN GENERAL- The directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall continue to conduct and support research to expand understanding of the causes of, and to find a cure for, psoriasis and psoriatic arthritis, including the following: (A) Basic research to discover the pathogenesis and pathophysiology of the disease. (B) Expansion of molecular biology and immunology studies, including additional animal models. (C) Global association mapping with single nucleotide polymorphisms. (D) Identification of environmental triggers and autoantigens in psoriasis . (E) Elucidation of specific immunologic cells and their products involved. (F) Pharmacogenetic studies to understand the molecular basis for varying patient response to treatment. (G) Identification of genetic markers of psoriatic arthritis susceptibility. (H) Research to increase understanding of joint inflammation and destruction in psoriatic arthritis. (I) Investigator-initiated clinical research for the development and evaluation of new treatments, including new biological agents. (J) Research to develop enhanced diagnostic tests that allow for earlier diagnosis of psoriasis and improved outcomes. (K) Research to increase understanding of the epidemiology and pathophysiology of co-morbidities associated with psoriasis , including shared molecular pathways. (2) COORDINATION WITH OTHER INSTITUTES- In carrying out paragraph (1), the directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall coordinate the activities of such Institutes with the activities of other national research institutes and other agencies and offices of the National Institutes of Health relating to psoriasis or psoriatic arthritis. SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 6. NATIONAL SUMMIT. (a) In General- Not later than one year after the date of the enactment of this Act, the Secretary is encouraged to convene a summit on the Federal Government's current and future efforts, and the initiatives necessary to fill any gaps, with respect to the conduct or support of psoriasis and psoriatic arthritis research, treatment, education, quality-of-life, and data collection activities. The summit should also address psoriasis and psoriatic arthritis related co-morbidities and should include researchers, public health professionals, representatives of voluntary health agencies and patient advocacy organizations, representatives of academic institutions, representatives from the pharmaceutical and medical research industry, and Federal and State policymakers, including representatives of the Agency for Healthcare Research and Quality, the Centers for Disease Control and Prevention, the Food and Drug Administration, and the National Institutes of Health. (b) Focus- The summit convened under this section should focus on-- (1) a broad range of research activities relating to biomedical, epidemiological, psychosocial, and rehabilitative issues; (2) clinical research for the development and evaluation of new treatments, including new biological agents; (3) translational research; (4) information and education programs for health care professionals and the public; (5) priorities among the programs and activities of the various Federal agencies involved in psoriasis and psoriatic arthritis and related co-morbidities; and (6) challenges, opportunities, and recommendations for scientists, clinicians, patients, and voluntary organizations. (c) Report to Congress- Not later than 180 days after the first day of the summit convened under this section, the Secretary shall submit to the Congress and make publicly available a report that includes a description of-- (1) the proceedings at the summit; and (2) recommendations related to the research, treatment, education, and quality-of-life activities conducted or supported by the Federal Government with respect to psoriasis and psoriatic arthritis, including psoriasis and psoriatic arthritis related co-morbidities.

Access to care for people with psoriasis and psoriatic arthritis H.R. 930 and S. 571, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009 SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 7. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE. (a) In General- The Secretary shall enter into an agreement with the Institute of Medicine to conduct a study on the following: (1) The extent to which public and private insurers cover prescription medications and other treatments for psoriasis and psoriatic arthritis. (2) The payment structures, such as deductibles and co-payments, and the amounts and duration of coverage under health plans and their adequacy to cover the costs of providing ongoing care to, and ensure access for, patients with psoriasis and psoriatic arthritis. (3) Health plan and insurer coverage policies and practices, including lifetime caps, and their impact on the access of such patients to the best regimen and most appropriate care for their particular disease state. (b) Report- The agreement entered into under subsection (a) shall provide for the Institute of Medicine to submit to the Secretary and the Congress, not later than 18 months after the date of the enactment of this Act, a report containing a description of-- (1) the results of the study conducted under this section; and (2) the conclusions and recommendations of the Institutes of Medicine regarding each of the issues described in paragraphs (1) through (3) of subsection (a).

H.R. 930: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 S. 571: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 SEC. 4. EXPANSION OF BIOMEDICAL RESEARCH. (a) In General- The Secretary of Health and Human Services (in this Act referred to as the `Secretary'), acting through the Director of the National Institutes of Health, shall continue to expand and intensify research and related activities of the Institutes with respect to psoriasis and psoriatic arthritis. (b) Research by National Institute of Arthritis and Musculoskeletal and Skin Diseases- (1) IN GENERAL- The directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall continue to conduct and support research to expand understanding of the causes of, and to find a cure for, psoriasis and psoriatic arthritis, including the following: (A) Basic research to discover the pathogenesis and pathophysiology of the disease. (B) Expansion of molecular biology and immunology studies, including additional animal models. (C) Global association mapping with single nucleotide polymorphisms. (D) Identification of environmental triggers and autoantigens in psoriasis . (E) Elucidation of specific immunologic cells and their products involved. (F) Pharmacogenetic studies to understand the molecular basis for varying patient response to treatment. (G) Identification of genetic markers of psoriatic arthritis susceptibility. (H) Research to increase understanding of joint inflammation and destruction in psoriatic arthritis. (I) Investigator-initiated clinical research for the development and evaluation of new treatments, including new biological agents. (J) Research to develop enhanced diagnostic tests that allow for earlier diagnosis of psoriasis and improved outcomes. (K) Research to increase understanding of the epidemiology and pathophysiology of co-morbidities associated with psoriasis , including shared molecular pathways. (2) COORDINATION WITH OTHER INSTITUTES- In carrying out paragraph (1), the directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall coordinate the activities of such Institutes with the activities of other national research institutes and other agencies and offices of the National Institutes of Health relating to psoriasis or psoriatic arthritis. SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 6. NATIONAL SUMMIT. (a) In General- Not later than one year after the date of the enactment of this Act, the Secretary is encouraged to convene a summit on the Federal Government's current and future efforts, and the initiatives necessary to fill any gaps, with respect to the conduct or support of psoriasis and psoriatic arthritis research, treatment, education, quality-of-life, and data collection activities. The summit should also address psoriasis and psoriatic arthritis related co-morbidities and should include researchers, public health professionals, representatives of voluntary health agencies and patient advocacy organizations, representatives of academic institutions, representatives from the pharmaceutical and medical research industry, and Federal and State policymakers, including representatives of the Agency for Healthcare Research and Quality, the Centers for Disease Control and Prevention, the Food and Drug Administration, and the National Institutes of Health. (b) Focus- The summit convened under this section should focus on-- (1) a broad range of research activities relating to biomedical, epidemiological, psychosocial, and rehabilitative issues; (2) clinical research for the development and evaluation of new treatments, including new biological agents; (3) translational research; (4) information and education programs for health care professionals and the public; (5) priorities among the programs and activities of the various Federal agencies involved in psoriasis and psoriatic arthritis and related co-morbidities; and (6) challenges, opportunities, and recommendations for scientists, clinicians, patients, and voluntary organizations. (c) Report to Congress- Not later than 180 days after the first day of the summit convened under this section, the Secretary shall submit to the Congress and make publicly available a report that includes a description of-- (1) the proceedings at the summit; and (2) recommendations related to the research, treatment, education, and quality-of-life activities conducted or supported by the Federal Government with respect to psoriasis and psoriatic arthritis, including psoriasis and psoriatic arthritis related co-morbidities.

H.R. 930, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009 S. 571, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009 SEC. 4. EXPANSION OF BIOMEDICAL RESEARCH. (a) In General- The Secretary of Health and Human Services (in this Act referred to as the `Secretary'), acting through the Director of the National Institutes of Health, shall continue to expand and intensify research and related activities of the Institutes with respect to psoriasis and psoriatic arthritis. (b) Research by National Institute of Arthritis and Musculoskeletal and Skin Diseases- (1) IN GENERAL- The directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall continue to conduct and support research to expand understanding of the causes of, and to find a cure for, psoriasis and psoriatic arthritis, including the following: (A) Basic research to discover the pathogenesis and pathophysiology of the disease. (B) Expansion of molecular biology and immunology studies, including additional animal models. (C) Global association mapping with single nucleotide polymorphisms. (D) Identification of environmental triggers and autoantigens in psoriasis. (E) Elucidation of specific immunologic cells and their products involved. (F) Pharmacogenetic studies to understand the molecular basis for varying patient response to treatment. (G) Identification of genetic markers of psoriatic arthritis susceptibility. (H) Research to increase understanding of joint inflammation and destruction in psoriatic arthritis. (I) Investigator-initiated clinical research for the development and evaluation of new treatments, including new biological agents. (J) Research to develop enhanced diagnostic tests that allow for earlier diagnosis of psoriasis and improved outcomes. (K) Research to increase understanding of the epidemiology and pathophysiology of co-morbidities associated with psoriasis, including shared molecular pathways. (2) COORDINATION WITH OTHER INSTITUTES- In carrying out paragraph (1), the directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall coordinate the activities of such Institutes with the activities of other national research institutes and other agencies and offices of the National Institutes of Health relating to psoriasis or psoriatic arthritis. SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 6. NATIONAL SUMMIT. (a) In General- Not later than one year after the date of the enactment of this Act, the Secretary is encouraged to convene a summit on the Federal Government's current and future efforts, and the initiatives necessary to fill any gaps, with respect to the conduct or support of psoriasis and psoriatic arthritis research, treatment, education, quality-of-life, and data collection activities. The summit should also address psoriasis and psoriatic arthritis related co-morbidities and should include researchers, public health professionals, representatives of voluntary health agencies and patient advocacy organizations, representatives of academic institutions, representatives from the pharmaceutical and medical research industry, and Federal and State policymakers, including representatives of the Agency for Healthcare Research and Quality, the Centers for Disease Control and Prevention, the Food and Drug Administration, and the National Institutes of Health. (b) Focus- The summit convened under this section should focus on-- (1) a broad range of research activities relating to biomedical, epidemiological, psychosocial, and rehabilitative issues; (2) clinical research for the development and evaluation of new treatments, including new biological agents; (3) translational research; (4) information and education programs for health care professionals and the public; (5) priorities among the programs and activities of the various Federal agencies involved in psoriasis and psoriatic arthritis and related co-morbidities; and (6) challenges, opportunities, and recommendations for scientists, clinicians, patients, and voluntary organizations. (c) Report to Congress- Not later than 180 days after the first day of the summit convened under this section, the Secretary shall submit to the Congress and make publicly available a report that includes a description of-- (1) the proceedings at the summit; and (2) recommendations related to the research, treatment, education, and quality-of-life activities conducted or supported by the Federal Government with respect to psoriasis and psoriatic arthritis, including psoriasis and psoriatic arthritis related co-morbidities.

H.R. 930: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 S. 571: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 SEC. 4. EXPANSION OF BIOMEDICAL RESEARCH. (a) In General- The Secretary of Health and Human Services (in this Act referred to as the `Secretary'), acting through the Director of the National Institutes of Health, shall continue to expand and intensify research and related activities of the Institutes with respect to psoriasis and psoriatic arthritis. (b) Research by National Institute of Arthritis and Musculoskeletal and Skin Diseases- (1) IN GENERAL- The directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall continue to conduct and support research to expand understanding of the causes of, and to find a cure for, psoriasis and psoriatic arthritis, including the following: (A) Basic research to discover the pathogenesis and pathophysiology of the disease. (B) Expansion of molecular biology and immunology studies, including additional animal models. (C) Global association mapping with single nucleotide polymorphisms. (D) Identification of environmental triggers and autoantigens in psoriasis . (E) Elucidation of specific immunologic cells and their products involved. (F) Pharmacogenetic studies to understand the molecular basis for varying patient response to treatment. (G) Identification of genetic markers of psoriatic arthritis susceptibility. (H) Research to increase understanding of joint inflammation and destruction in psoriatic arthritis. (I) Investigator-initiated clinical research for the development and evaluation of new treatments, including new biological agents. (J) Research to develop enhanced diagnostic tests that allow for earlier diagnosis of psoriasis and improved outcomes. (K) Research to increase understanding of the epidemiology and pathophysiology of co-morbidities associated with psoriasis , including shared molecular pathways. (2) COORDINATION WITH OTHER INSTITUTES- In carrying out paragraph (1), the directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall coordinate the activities of such Institutes with the activities of other national research institutes and other agencies and offices of the National Institutes of Health relating to psoriasis or psoriatic arthritis. SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 6. NATIONAL SUMMIT. (a) In General- Not later than one year after the date of the enactment of this Act, the Secretary is encouraged to convene a summit on the Federal Government's current and future efforts, and the initiatives necessary to fill any gaps, with respect to the conduct or support of psoriasis and psoriatic arthritis research, treatment, education, quality-of-life, and data collection activities. The summit should also address psoriasis and psoriatic arthritis related co-morbidities and should include researchers, public health professionals, representatives of voluntary health agencies and patient advocacy organizations, representatives of academic institutions, representatives from the pharmaceutical and medical research industry, and Federal and State policymakers, including representatives of the Agency for Healthcare Research and Quality, the Centers for Disease Control and Prevention, the Food and Drug Administration, and the National Institutes of Health. (b) Focus- The summit convened under this section should focus on-- (1) a broad range of research activities relating to biomedical, epidemiological, psychosocial, and rehabilitative issues; (2) clinical research for the development and evaluation of new treatments, including new biological agents; (3) translational research; (4) information and education programs for health care professionals and the public; (5) priorities among the programs and activities of the various Federal agencies involved in psoriasis and psoriatic arthritis and related co-morbidities; and (6) challenges, opportunities, and recommendations for scientists, clinicians, patients, and voluntary organizations. (c) Report to Congress- Not later than 180 days after the first day of the summit convened under this section, the Secretary shall submit to the Congress and make publicly available a report that includes a description of-- (1) the proceedings at the summit; and (2) recommendations related to the research, treatment, education, and quality-of-life activities conducted or supported by the Federal Government with respect to psoriasis and psoriatic arthritis, including psoriasis and psoriatic arthritis related co-morbidities.

Access to care for people with psoriasis and psoriatic arthritis H.R. 930 and S. 571, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009 SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 7. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE. (a) In General- The Secretary shall enter into an agreement with the Institute of Medicine to conduct a study on the following: (1) The extent to which public and private insurers cover prescription medications and other treatments for psoriasis and psoriatic arthritis. (2) The payment structures, such as deductibles and co-payments, and the amounts and duration of coverage under health plans and their adequacy to cover the costs of providing ongoing care to, and ensure access for, patients with psoriasis and psoriatic arthritis. (3) Health plan and insurer coverage policies and practices, including lifetime caps, and their impact on the access of such patients to the best regimen and most appropriate care for their particular disease state. (b) Report- The agreement entered into under subsection (a) shall provide for the Institute of Medicine to submit to the Secretary and the Congress, not later than 18 months after the date of the enactment of this Act, a report containing a description of-- (1) the results of the study conducted under this section; and (2) the conclusions and recommendations of the Institutes of Medicine regarding each of the issues described in paragraphs (1) through (3) of subsection (a).

H.R. 930: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 S. 571: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 SEC. 4. EXPANSION OF BIOMEDICAL RESEARCH. (a) In General- The Secretary of Health and Human Services (in this Act referred to as the `Secretary'), acting through the Director of the National Institutes of Health, shall continue to expand and intensify research and related activities of the Institutes with respect to psoriasis and psoriatic arthritis. (b) Research by National Institute of Arthritis and Musculoskeletal and Skin Diseases- (1) IN GENERAL- The directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall continue to conduct and support research to expand understanding of the causes of, and to find a cure for, psoriasis and psoriatic arthritis, including the following: (A) Basic research to discover the pathogenesis and pathophysiology of the disease. (B) Expansion of molecular biology and immunology studies, including additional animal models. (C) Global association mapping with single nucleotide polymorphisms. (D) Identification of environmental triggers and autoantigens in psoriasis . (E) Elucidation of specific immunologic cells and their products involved. (F) Pharmacogenetic studies to understand the molecular basis for varying patient response to treatment. (G) Identification of genetic markers of psoriatic arthritis susceptibility. (H) Research to increase understanding of joint inflammation and destruction in psoriatic arthritis. (I) Investigator-initiated clinical research for the development and evaluation of new treatments, including new biological agents. (J) Research to develop enhanced diagnostic tests that allow for earlier diagnosis of psoriasis and improved outcomes. (K) Research to increase understanding of the epidemiology and pathophysiology of co-morbidities associated with psoriasis , including shared molecular pathways. (2) COORDINATION WITH OTHER INSTITUTES- In carrying out paragraph (1), the directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall coordinate the activities of such Institutes with the activities of other national research institutes and other agencies and offices of the National Institutes of Health relating to psoriasis or psoriatic arthritis. SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 6. NATIONAL SUMMIT. (a) In General- Not later than one year after the date of the enactment of this Act, the Secretary is encouraged to convene a summit on the Federal Government's current and future efforts, and the initiatives necessary to fill any gaps, with respect to the conduct or support of psoriasis and psoriatic arthritis research, treatment, education, quality-of-life, and data collection activities. The summit should also address psoriasis and psoriatic arthritis related co-morbidities and should include researchers, public health professionals, representatives of voluntary health agencies and patient advocacy organizations, representatives of academic institutions, representatives from the pharmaceutical and medical research industry, and Federal and State policymakers, including representatives of the Agency for Healthcare Research and Quality, the Centers for Disease Control and Prevention, the Food and Drug Administration, and the National Institutes of Health. (b) Focus- The summit convened under this section should focus on-- (1) a broad range of research activities relating to biomedical, epidemiological, psychosocial, and rehabilitative issues; (2) clinical research for the development and evaluation of new treatments, including new biological agents; (3) translational research; (4) information and education programs for health care professionals and the public; (5) priorities among the programs and activities of the various Federal agencies involved in psoriasis and psoriatic arthritis and related co-morbidities; and (6) challenges, opportunities, and recommendations for scientists, clinicians, patients, and voluntary organizations. (c) Report to Congress- Not later than 180 days after the first day of the summit convened under this section, the Secretary shall submit to the Congress and make publicly available a report that includes a description of-- (1) the proceedings at the summit; and (2) recommendations related to the research, treatment, education, and quality-of-life activities conducted or supported by the Federal Government with respect to psoriasis and psoriatic arthritis, including psoriasis and psoriatic arthritis related co-morbidities.

Access to care for people with psoriasis and psoriatic arthritis H.R. 930 and S. 571, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009 SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 7. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE. (a) In General- The Secretary shall enter into an agreement with the Institute of Medicine to conduct a study on the following: (1) The extent to which public and private insurers cover prescription medications and other treatments for psoriasis and psoriatic arthritis. (2) The payment structures, such as deductibles and co-payments, and the amounts and duration of coverage under health plans and their adequacy to cover the costs of providing ongoing care to, and ensure access for, patients with psoriasis and psoriatic arthritis. (3) Health plan and insurer coverage policies and practices, including lifetime caps, and their impact on the access of such patients to the best regimen and most appropriate care for their particular disease state. (b) Report- The agreement entered into under subsection (a) shall provide for the Institute of Medicine to submit to the Secretary and the Congress, not later than 18 months after the date of the enactment of this Act, a report containing a description of-- (1) the results of the study conducted under this section; and (2) the conclusions and recommendations of the Institutes of Medicine regarding each of the issues described in paragraphs (1) through (3) of subsection (a).

Access to care for people with psoriasis and psoriatic arthritis H.R. 930 and S. 571, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009 SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 7. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE. (a) In General- The Secretary shall enter into an agreement with the Institute of Medicine to conduct a study on the following: (1) The extent to which public and private insurers cover prescription medications and other treatments for psoriasis and psoriatic arthritis. (2) The payment structures, such as deductibles and co-payments, and the amounts and duration of coverage under health plans and their adequacy to cover the costs of providing ongoing care to, and ensure access for, patients with psoriasis and psoriatic arthritis. (3) Health plan and insurer coverage policies and practices, including lifetime caps, and their impact on the access of such patients to the best regimen and most appropriate care for their particular disease state. (b) Report- The agreement entered into under subsection (a) shall provide for the Institute of Medicine to submit to the Secretary and the Congress, not later than 18 months after the date of the enactment of this Act, a report containing a description of-- (1) the results of the study conducted under this section; and (2) the conclusions and recommendations of the Institutes of Medicine regarding each of the issues described in paragraphs (1) through (3) of subsection (a).

Access to care for people with psoriasis and psoriatic arthritis H.R. 930 and S. 571, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009 H.R. 930 and S. 571, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009 SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 7. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE. (a) In General- The Secretary shall enter into an agreement with the Institute of Medicine to conduct a study on the following: (1) The extent to which public and private insurers cover prescription medications and other treatments for psoriasis and psoriatic arthritis. (2) The payment structures, such as deductibles and co-payments, and the amounts and duration of coverage under health plans and their adequacy to cover the costs of providing ongoing care to, and ensure access for, patients with psoriasis and psoriatic arthritis. (3) Health plan and insurer coverage policies and practices, including lifetime caps, and their impact on the access of such patients to the best regimen and most appropriate care for their particular disease state. (b) Report- The agreement entered into under subsection (a) shall provide for the Institute of Medicine to submit to the Secretary and the Congress, not later than 18 months after the date of the enactment of this Act, a report containing a description of-- (1) the results of the study conducted under this section; and (2) the conclusions and recommendations of the Institutes of Medicine regarding each of the issues described in paragraphs (1) through (3) of subsection (a).

H.R. 930, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009 S. 571, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009 SEC. 4. EXPANSION OF BIOMEDICAL RESEARCH. (a) In General- The Secretary of Health and Human Services (in this Act referred to as the `Secretary'), acting through the Director of the National Institutes of Health, shall continue to expand and intensify research and related activities of the Institutes with respect to psoriasis and psoriatic arthritis. (b) Research by National Institute of Arthritis and Musculoskeletal and Skin Diseases- (1) IN GENERAL- The directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall continue to conduct and support research to expand understanding of the causes of, and to find a cure for, psoriasis and psoriatic arthritis, including the following: (A) Basic research to discover the pathogenesis and pathophysiology of the disease. (B) Expansion of molecular biology and immunology studies, including additional animal models. (C) Global association mapping with single nucleotide polymorphisms. (D) Identification of environmental triggers and autoantigens in psoriasis . (E) Elucidation of specific immunologic cells and their products involved. (F) Pharmacogenetic studies to understand the molecular basis for varying patient response to treatment. (G) Identification of genetic markers of psoriatic arthritis susceptibility. (H) Research to increase understanding of joint inflammation and destruction in psoriatic arthritis. (I) Investigator-initiated clinical research for the development and evaluation of new treatments, including new biological agents. (J) Research to develop enhanced diagnostic tests that allow for earlier diagnosis of psoriasis and improved outcomes. (K) Research to increase understanding of the epidemiology and pathophysiology of co-morbidities associated with psoriasis , including shared molecular pathways. (2) COORDINATION WITH OTHER INSTITUTES- In carrying out paragraph (1), the directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall coordinate the activities of such Institutes with the activities of other national research institutes and other agencies and offices of the National Institutes of Health relating to psoriasis or psoriatic arthritis. SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY. The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry. SEC. 6. NATIONAL SUMMIT. (a) In General- Not later than one year after the date of the enactment of this Act, the Secretary is encouraged to convene a summit on the Federal Government's current and future efforts, and the initiatives necessary to fill any gaps, with respect to the conduct or support of psoriasis and psoriatic arthritis research, treatment, education, quality-of-life, and data collection activities. The summit should also address psoriasis and psoriatic arthritis related co-morbidities and should include researchers, public health professionals, representatives of voluntary health agencies and patient advocacy organizations, representatives of academic institutions, representatives from the pharmaceutical and medical research industry, and Federal and State policymakers, including representatives of the Agency for Healthcare Research and Quality, the Centers for Disease Control and Prevention, the Food and Drug Administration, and the National Institutes of Health. (b) Focus- The summit convened under this section should focus on-- (1) a broad range of research activities relating to biomedical, epidemiological, psychosocial, and rehabilitative issues; (2) clinical research for the development and evaluation of new treatments, including new biological agents; (3) translational research; (4) information and education programs for health care professionals and the public; (5) priorities among the programs and activities of the various Federal agencies involved in psoriasis and psoriatic arthritis and related co-morbidities; and (6) challenges, opportunities, and recommendations for scientists, clinicians, patients, and voluntary organizations. (c) Report to Congress- Not later than 180 days after the first day of the summit convened under this section, the Secretary shall submit to the Congress and make publicly available a report that includes a description of-- (1) the proceedings at the summit; and (2) recommendations related to the research, treatment, education, and quality-of-life activities conducted or supported by the Federal Government with respect to psoriasis and psoriatic arthritis, including psoriasis and psoriatic arthritis related co-morbidities.

Access to care for people with psoriasis and psoriatic arthritis H.R. 1188 and S. 1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 H.R.1188 and S.1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 Section 104. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE Directs the HHS Secretary to enter into a contract with the Institute of Medicine (IOM) to conduct a study to evaluate and make recommendations to address the following: (1) The extent to which public and private insurers cover prescription medications and other treatments for psoriasis and psoriatic arthritis; (2) The payment structures, such as deductibles and co-payments, amounts and duration of the coverage and payments under health plans and their adequacy to cover the costs of providing ongoing care to patients with psoriasis and psoriatic arthritis; (3) Health plan and insurer coverage policies and practices and their impact on patient access to the best regimen and most appropriate care for their particular disease state.

H.R. 1188, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 S. 1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 H.R.1188 and S.1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 Section 101. EXPANSION OF BIOMEDICAL RESEARCH Directs the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) to expand and intensify research on psoriasis and psoriatic arthritis. Directs NIAMS to coordinate with other National Institutes of Health (NIH) centers, institutes, and offices with respect to psoriasis and psoriatic arthritis research. Section 102. STRENGTHENING PSORIASIS AND PSORIATIC ARTHRITIS EPIDEMIOLOGY Directs the Centers for Disease Control and Prevention (CDC), in collaboration with a national organization expert in the epidemiology of psoriasis and psoriatic arthritis, to establish a national psoriasis and psoriatic arthritis patient registry. Section 103. PSORIASIS AND PSORIATIC ARTHRITIS CO-MORBIDITIES CONDITIONS SUMMIT Directs the Department of Health and Human Services (HHS) to convene a summit of researchers, public health professionals, patient advocacy organizations, academic institutions, and Federal and State policymakers to provide a detailed overview of current efforts in psoriasis and psoriatic arthritis research, treatment, quality of life, and other such activities at the NIH, CDC, the Agency for Healthcare Research and Quality, the Substance Abuse and Mental Health Services Administration, and the Health Resources and Services Administration, and other federal agencies whose work involves psoriasis and psoriatic arthritis related co-morbidities. Requires a report to Congress not later than 180 days after the convening of summit.

H.R. 1188, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 S. 1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 H.R.1188 and S.1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 Section 101. EXPANSION OF BIOMEDICAL RESEARCH Directs the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) to expand and intensify research on psoriasis and psoriatic arthritis. Directs NIAMS to coordinate with other National Institutes of Health (NIH) centers, institutes, and offices with respect to psoriasis and psoriatic arthritis research. Section 102. STRENGTHENING PSORIASIS AND PSORIATIC ARTHRITIS EPIDEMIOLOGY Directs the Centers for Disease Control and Prevention (CDC), in collaboration with a national organization expert in the epidemiology of psoriasis and psoriatic arthritis, to establish a national psoriasis and psoriatic arthritis patient registry. Section 103. PSORIASIS AND PSORIATIC ARTHRITIS CO-MORBIDITIES CONDITIONS SUMMIT Directs the Department of Health and Human Services (HHS) to convene a summit of researchers, public health professionals, patient advocacy organizations, academic institutions, and Federal and State policymakers to provide a detailed overview of current efforts in psoriasis and psoriatic arthritis research, treatment, quality of life, and other such activities at the NIH, CDC, the Agency for Healthcare Research and Quality, the Substance Abuse and Mental Health Services Administration, and the Health Resources and Services Administration, and other federal agencies whose work involves psoriasis and psoriatic arthritis related co-morbidities. Requires a report to Congress not later than 180 days after the convening of summit.

Access to care for people with psoriasis and psoriatic arthritis H.R. 1188 and S. 1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 H.R.1188 and S.1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 Section 102. STRENGTHENING PSORIASIS AND PSORIATIC ARTHRITIS EPIDEMIOLOGY Directs the Centers for Disease Control and Prevention (CDC), in collaboration with a national organization expert in the epidemiology of psoriasis and psoriatic arthritis, to establish a national psoriasis and psoriatic arthritis patient registry. Section 104. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE Directs the HHS Secretary to enter into a contract with the Institute of Medicine (IOM) to conduct a study to evaluate and make recommendations to address the following: (1) The extent to which public and private insurers cover prescription medications and other treatments for psoriasis and psoriatic arthritis; (2) The payment structures, such as deductibles and co-payments, amounts and duration of the coverage and payments under health plans and their adequacy to cover the costs of providing ongoing care to patients with psoriasis and psoriatic arthritis; (3) Health plan and insurer coverage policies and practices and their impact on patient access to the best regimen and most appropriate care for their particular disease state.

Access to care for people with psoriasis and psoriatic arthritis H.R. 1188, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 S. 1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 H.R.1188 and S.1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 Section 104. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE Directs the HHS Secretary to enter into a contract with the Institute of Medicine (IOM) to conduct a study to evaluate and make recommendations to address the following: (1) The extent to which public and private insurers cover prescription medications and other treatments for psoriasis and psoriatic arthritis; (2) The payment structures, such as deductibles and co-payments, amounts and duration of the coverage and payments under health plans and their adequacy to cover the costs of providing ongoing care to patients with psoriasis and psoriatic arthritis; (3) Health plan and insurer coverage policies and practices and their impact on patient access to the best regimen and most appropriate care for their particular disease state.

H.R. 1188, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 S. 1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 H.R.1188 and S.1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 Section 101. EXPANSION OF BIOMEDICAL RESEARCH Directs the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) to expand and intensify research on psoriasis and psoriatic arthritis. Directs NIAMS to coordinate with other National Institutes of Health (NIH) centers, institutes, and offices with respect to psoriasis and psoriatic arthritis research. Section 102. STRENGTHENING PSORIASIS AND PSORIATIC ARTHRITIS EPIDEMIOLOGY Directs the Centers for Disease Control and Prevention (CDC), in collaboration with a national organization expert in the epidemiology of psoriasis and psoriatic arthritis, to establish a national psoriasis and psoriatic arthritis patient registry. Section 103. PSORIASIS AND PSORIATIC ARTHRITIS CO-MORBIDITIES CONDITIONS SUMMIT Directs the Department of Health and Human Services (HHS) to convene a summit of researchers, public health professionals, patient advocacy organizations, academic institutions, and Federal and State policymakers to provide a detailed overview of current efforts in psoriasis and psoriatic arthritis research, treatment, quality of life, and other such activities at the NIH, CDC, the Agency for Healthcare Research and Quality, the Substance Abuse and Mental Health Services Administration, and the Health Resources and Services Administration, and other federal agencies whose work involves psoriasis and psoriatic arthritis related co-morbidities. Requires a report to Congress not later than 180 days after the convening of summit.

Access to care for people with psoriasis and psoriatic arthritis H.R. 1188, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 S. 1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 H.R.1188 and S.1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 Section 104. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE Directs the HHS Secretary to enter into a contract with the Institute of Medicine (IOM) to conduct a study to evaluate and make recommendations to address the following: (1) The extent to which public and private insurers cover prescription medications and other treatments for psoriasis and psoriatic arthritis; (2) The payment structures, such as deductibles and co-payments, amounts and duration of the coverage and payments under health plans and their adequacy to cover the costs of providing ongoing care to patients with psoriasis and psoriatic arthritis; (3) Health plan and insurer coverage policies and practices and their impact on patient access to the best regimen and most appropriate care for their particular disease state.

H.R. 1188, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 S. 1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 H.R.1188 and S.1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 Section 101. EXPANSION OF BIOMEDICAL RESEARCH Directs the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) to expand and intensify research on psoriasis and psoriatic arthritis. Directs NIAMS to coordinate with other National Institutes of Health (NIH) centers, institutes, and offices with respect to psoriasis and psoriatic arthritis research. Section 102. STRENGTHENING PSORIASIS AND PSORIATIC ARTHRITIS EPIDEMIOLOGY Directs the Centers for Disease Control and Prevention (CDC), in collaboration with a national organization expert in the epidemiology of psoriasis and psoriatic arthritis, to establish a national psoriasis and psoriatic arthritis patient registry. Section 103. PSORIASIS AND PSORIATIC ARTHRITIS CO-MORBIDITIES CONDITIONS SUMMIT Directs the Department of Health and Human Services (HHS) to convene a summit of researchers, public health professionals, patient advocacy organizations, academic institutions, and Federal and State policymakers to provide a detailed overview of current efforts in psoriasis and psoriatic arthritis research, treatment, quality of life, and other such activities at the NIH, CDC, the Agency for Healthcare Research and Quality, the Substance Abuse and Mental Health Services Administration, and the Health Resources and Services Administration, and other federal agencies whose work involves psoriasis and psoriatic arthritis related co-morbidities. Requires a report to Congress not later than 180 days after the convening of summit.

H.R. 2833 and S. 2236, Preexisting Condition Exclusion Patient Protection Act H.R. 2842 and S. 3115, Children's Health Protection Act H.R. 2833 and S. 2236, Preexisting Condition Exclusion Patient Protection Act A bill to amend title I of the Employee Retirement Income Security Act of 1974, title XXVII of the Public Health Service Act, and the Internal Revenue Code of 1986 to prohibit preexisting condition exclusions for children in group health plans and health insurance coverage in the group and individual markets. H.R. 2842 and S. 3115, Children's Health Protection Act To amend title I of the Employee Retirement Income Security Act of 1974, title XXVII of the Public Health Service Act, and the Internal Revenue Code of 1986 to prohibit preexisting condition exclusions for children in group health plans and health insurance coverage in the group and individual markets.

H.R. 2833 and S. 2236, Preexisting Condition Exclusion Patient Protection Act H.R. 2842 and S. 3115, Children's Health Protection Act H.R. 2833 and S. 2236, Preexisting Condition Exclusion Patient Protection Act A bill to amend title I of the Employee Retirement Income Security Act of 1974, title XXVII of the Public Health Service Act, and the Internal Revenue Code of 1986 to prohibit preexisting condition exclusions for children in group health plans and health insurance coverage in the group and individual markets. H.R. 2842 and S. 3115, Children's Health Protection Act To amend title I of the Employee Retirement Income Security Act of 1974, title XXVII of the Public Health Service Act, and the Internal Revenue Code of 1986 to prohibit preexisting condition exclusions for children in group health plans and health insurance coverage in the group and individual markets.

H.R. 2833 and S. 2236, Preexisting Condition Exclusion Patient Protection Act H.R. 2842 and S. 3115, Children's Health Protection Act H.R. 2833 and S. 2236, Preexisting Condition Exclusion Patient Protection Act A bill to amend title I of the Employee Retirement Income Security Act of 1974, title XXVII of the Public Health Service Act, and the Internal Revenue Code of 1986 to prohibit preexisting condition exclusions for children in group health plans and health insurance coverage in the group and individual markets. H.R. 2842 and S. 3115, Children's Health Protection Act To amend title I of the Employee Retirement Income Security Act of 1974, title XXVII of the Public Health Service Act, and the Internal Revenue Code of 1986 to prohibit preexisting condition exclusions for children in group health plans and health insurance coverage in the group and individual markets.

H.R. 2833 and S. 2236, Preexisting Condition Exclusion Patient Protection Act H.R. 2842 and S. 3115, Children's Health Protection Act H.R. 2833 and S. 2236, Preexisting Condition Exclusion Patient Protection Act A bill to amend title I of the Employee Retirement Income Security Act of 1974, title XXVII of the Public Health Service Act, and the Internal Revenue Code of 1986 to prohibit preexisting condition exclusions for children in group health plans and health insurance coverage in the group and individual markets. H.R. 2842 and S. 3115, Children's Health Protection Act To amend title I of the Employee Retirement Income Security Act of 1974, title XXVII of the Public Health Service Act, and the Internal Revenue Code of 1986 to prohibit preexisting condition exclusions for children in group health plans and health insurance coverage in the group and individual markets.

H.R. 1188, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 S. 1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 H.R.1188 and S.1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 Section 101. EXPANSION OF BIOMEDICAL RESEARCH Directs the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) to expand and intensify research on psoriasis and psoriatic arthritis. Directs NIAMS to coordinate with other National Institutes of Health (NIH) centers, institutes, and offices with respect to psoriasis and psoriatic arthritis research. Section 102. STRENGTHENING PSORIASIS AND PSORIATIC ARTHRITIS EPIDEMIOLOGY Directs the Centers for Disease Control and Prevention (CDC), in collaboration with a national organization expert in the epidemiology of psoriasis and psoriatic arthritis, to establish a national psoriasis and psoriatic arthritis patient registry. Section 103. PSORIASIS AND PSORIATIC ARTHRITIS CO-MORBIDITIES CONDITIONS SUMMIT Directs the Department of Health and Human Services (HHS) to convene a summit of researchers, public health professionals, patient advocacy organizations, academic institutions, and Federal and State policymakers to provide a detailed overview of current efforts in psoriasis and psoriatic arthritis research, treatment, quality of life, and other such activities at the NIH, CDC, the Agency for Healthcare Research and Quality, the Substance Abuse and Mental Health Services Administration, and the Health Resources and Services Administration, and other federal agencies whose work involves psoriasis and psoriatic arthritis related co-morbidities. Requires a report to Congress not later than 180 days after the convening of summit.

Access to care for people with psoriasis and psoriatic arthritis H.R. 1188, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 S. 1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 H.R.1188 and S.1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 Section 104. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE Directs the HHS Secretary to enter into a contract with the Institute of Medicine (IOM) to conduct a study to evaluate and make recommendations to address the following: (1) The extent to which public and private insurers cover prescription medications and other treatments for psoriasis and psoriatic arthritis; (2) The payment structures, such as deductibles and co-payments, amounts and duration of the coverage and payments under health plans and their adequacy to cover the costs of providing ongoing care to patients with psoriasis and psoriatic arthritis; (3) Health plan and insurer coverage policies and practices and their impact on patient access to the best regimen and most appropriate care for their particular disease state.

H.R. 1188, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 S. 1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 H.R.1188 and S.1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 Section 101. EXPANSION OF BIOMEDICAL RESEARCH Directs the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) to expand and intensify research on psoriasis and psoriatic arthritis. Directs NIAMS to coordinate with other National Institutes of Health (NIH) centers, institutes, and offices with respect to psoriasis and psoriatic arthritis research. Section 102. STRENGTHENING PSORIASIS AND PSORIATIC ARTHRITIS EPIDEMIOLOGY Directs the Centers for Disease Control and Prevention (CDC), in collaboration with a national organization expert in the epidemiology of psoriasis and psoriatic arthritis, to establish a national psoriasis and psoriatic arthritis patient registry. Section 103. PSORIASIS AND PSORIATIC ARTHRITIS CO-MORBIDITIES CONDITIONS SUMMIT Directs the Department of Health and Human Services (HHS) to convene a summit of researchers, public health professionals, patient advocacy organizations, academic institutions, and Federal and State policymakers to provide a detailed overview of current efforts in psoriasis and psoriatic arthritis research, treatment, quality of life, and other such activities at the NIH, CDC, the Agency for Healthcare Research and Quality, the Substance Abuse and Mental Health Services Administration, and the Health Resources and Services Administration, and other federal agencies whose work involves psoriasis and psoriatic arthritis related co-morbidities. Requires a report to Congress not later than 180 days after the convening of summit.

Access to care for people with psoriasis and psoriatic arthritis H.R. 1188 and S. 1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 H.R.1188 and S.1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 Section 104. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE Directs the HHS Secretary to enter into a contract with the Institute of Medicine (IOM) to conduct a study to evaluate and make recommendations to address the following: (1) The extent to which public and private insurers cover prescription medications and other treatments for psoriasis and psoriatic arthritis; (2) The payment structures, such as deductibles and co-payments, amounts and duration of the coverage and payments under health plans and their adequacy to cover the costs of providing ongoing care to patients with psoriasis and psoriatic arthritis; (3) Health plan and insurer coverage policies and practices and their impact on patient access to the best regimen and most appropriate care for their particular disease state.

Access to care for people with psoriasis and psoriatic arthritis H.R. 1188, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 S. 1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 H.R.1188 and S.1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 Section 104. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE Directs the HHS Secretary to enter into a contract with the Institute of Medicine (IOM) to conduct a study to evaluate and make recommendations to address the following: (1) The extent to which public and private insurers cover prescription medications and other treatments for psoriasis and psoriatic arthritis; (2) The payment structures, such as deductibles and co-payments, amounts and duration of the coverage and payments under health plans and their adequacy to cover the costs of providing ongoing care to patients with psoriasis and psoriatic arthritis; (3) Health plan and insurer coverage policies and practices and their impact on patient access to the best regimen and most appropriate care for their particular disease state.

Access to care for people with psoriasis and psoriatic arthritis H.R. 1188 and S. 1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 H.R.1188 and S.1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 Section 102. STRENGTHENING PSORIASIS AND PSORIATIC ARTHRITIS EPIDEMIOLOGY Directs the Centers for Disease Control and Prevention (CDC), in collaboration with a national organization expert in the epidemiology of psoriasis and psoriatic arthritis, to establish a national psoriasis and psoriatic arthritis patient registry. Section 104. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE Directs the HHS Secretary to enter into a contract with the Institute of Medicine (IOM) to conduct a study to evaluate and make recommendations to address the following: (1) The extent to which public and private insurers cover prescription medications and other treatments for psoriasis and psoriatic arthritis; (2) The payment structures, such as deductibles and co-payments, amounts and duration of the coverage and payments under health plans and their adequacy to cover the costs of providing ongoing care to patients with psoriasis and psoriatic arthritis; (3) Health plan and insurer coverage policies and practices and their impact on patient access to the best regimen and most appropriate care for their particular disease state.

H.R. 1188, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 S. 1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 H.R.1188 and S.1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 Section 101. EXPANSION OF BIOMEDICAL RESEARCH Directs the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) to expand and intensify research on psoriasis and psoriatic arthritis. Directs NIAMS to coordinate with other National Institutes of Health (NIH) centers, institutes, and offices with respect to psoriasis and psoriatic arthritis research. Section 102. STRENGTHENING PSORIASIS AND PSORIATIC ARTHRITIS EPIDEMIOLOGY Directs the Centers for Disease Control and Prevention (CDC), in collaboration with a national organization expert in the epidemiology of psoriasis and psoriatic arthritis, to establish a national psoriasis and psoriatic arthritis patient registry. Section 103. PSORIASIS AND PSORIATIC ARTHRITIS CO-MORBIDITIES CONDITIONS SUMMIT Directs the Department of Health and Human Services (HHS) to convene a summit of researchers, public health professionals, patient advocacy organizations, academic institutions, and Federal and State policymakers to provide a detailed overview of current efforts in psoriasis and psoriatic arthritis research, treatment, quality of life, and other such activities at the NIH, CDC, the Agency for Healthcare Research and Quality, the Substance Abuse and Mental Health Services Administration, and the Health Resources and Services Administration, and other federal agencies whose work involves psoriasis and psoriatic arthritis related co-morbidities. Requires a report to Congress not later than 180 days after the convening of summit.

H.R. 1188, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 S. 1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 H.R.1188 and S.1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 Section 101. EXPANSION OF BIOMEDICAL RESEARCH Directs the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) to expand and intensify research on psoriasis and psoriatic arthritis. Directs NIAMS to coordinate with other National Institutes of Health (NIH) centers, institutes, and offices with respect to psoriasis and psoriatic arthritis research. Section 102. STRENGTHENING PSORIASIS AND PSORIATIC ARTHRITIS EPIDEMIOLOGY Directs the Centers for Disease Control and Prevention (CDC), in collaboration with a national organization expert in the epidemiology of psoriasis and psoriatic arthritis, to establish a national psoriasis and psoriatic arthritis patient registry. Section 103. PSORIASIS AND PSORIATIC ARTHRITIS CO-MORBIDITIES CONDITIONS SUMMIT Directs the Department of Health and Human Services (HHS) to convene a summit of researchers, public health professionals, patient advocacy organizations, academic institutions, and Federal and State policymakers to provide a detailed overview of current efforts in psoriasis and psoriatic arthritis research, treatment, quality of life, and other such activities at the NIH, CDC, the Agency for Healthcare Research and Quality, the Substance Abuse and Mental Health Services Administration, and the Health Resources and Services Administration, and other federal agencies whose work involves psoriasis and psoriatic arthritis related co-morbidities. Requires a report to Congress not later than 180 days after the convening of summit.

H.R.3043, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2008, Title 2, all provisions relating to National Institutes of Health and National Center for Health Statistics S.1710, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2008, Title 2, all provisions relating to National Institutes of Health and National Center for Health Statistics

H.R.3043, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2008, Title 2, all provisions relating to National Institutes of Health and National Center for Health Statistics S.1710, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2008, Title 2, all provisions relating to National Institutes of Health and National Center for Health Statistics

H.R. 2833 and S. 2236, Preexisting Condition Exclusion Patient Protection Act H.R. 2842 and S. 3115, Children's Health Protection Act H.R. 2833 and S. 2236, Preexisting Condition Exclusion Patient Protection Act A bill to amend title I of the Employee Retirement Income Security Act of 1974, title XXVII of the Public Health Service Act, and the Internal Revenue Code of 1986 to prohibit preexisting condition exclusions for children in group health plans and health insurance coverage in the group and individual markets. H.R. 2842 and S. 3115, Children's Health Protection Act To amend title I of the Employee Retirement Income Security Act of 1974, title XXVII of the Public Health Service Act, and the Internal Revenue Code of 1986 to prohibit preexisting condition exclusions for children in group health plans and health insurance coverage in the group and individual markets.

H.R. 2833 and S. 2236, Preexisting Condition Exclusion Patient Protection Act H.R. 2842 and S. 3115, Children's Health Protection Act H.R. 2833 and S. 2236, Preexisting Condition Exclusion Patient Protection Act A bill to amend title I of the Employee Retirement Income Security Act of 1974, title XXVII of the Public Health Service Act, and the Internal Revenue Code of 1986 to prohibit preexisting condition exclusions for children in group health plans and health insurance coverage in the group and individual markets. H.R. 2842 and S. 3115, Children's Health Protection Act To amend title I of the Employee Retirement Income Security Act of 1974, title XXVII of the Public Health Service Act, and the Internal Revenue Code of 1986 to prohibit preexisting condition exclusions for children in group health plans and health insurance coverage in the group and individual markets.

H.R. 2833 and S. 2236, Preexisting Condition Exclusion Patient Protection Act H.R. 2842 and S. 3115, Children's Health Protection Act H.R. 2833 and S. 2236, Preexisting Condition Exclusion Patient Protection Act A bill to amend title I of the Employee Retirement Income Security Act of 1974, title XXVII of the Public Health Service Act, and the Internal Revenue Code of 1986 to prohibit preexisting condition exclusions for children in group health plans and health insurance coverage in the group and individual markets. H.R. 2842 and S. 3115, Children's Health Protection Act To amend title I of the Employee Retirement Income Security Act of 1974, title XXVII of the Public Health Service Act, and the Internal Revenue Code of 1986 to prohibit preexisting condition exclusions for children in group health plans and health insurance coverage in the group and individual markets.

H.R. 2833 and S. 2236, Preexisting Condition Exclusion Patient Protection Act H.R. 2842 and S. 3115, Children's Health Protection Act H.R. 2833 and S. 2236, Preexisting Condition Exclusion Patient Protection Act A bill to amend title I of the Employee Retirement Income Security Act of 1974, title XXVII of the Public Health Service Act, and the Internal Revenue Code of 1986 to prohibit preexisting condition exclusions for children in group health plans and health insurance coverage in the group and individual markets. H.R. 2842 and S. 3115, Children's Health Protection Act To amend title I of the Employee Retirement Income Security Act of 1974, title XXVII of the Public Health Service Act, and the Internal Revenue Code of 1986 to prohibit preexisting condition exclusions for children in group health plans and health insurance coverage in the group and individual markets.

H.R. 3195 and S. 3406, ADA Amendments Act of 2008

S.358, Genetic Nondiscrimination Act S.358, Genetic Nondiscrimination Act: Title II: Prohibiting Employment Discrimination on the Basis of Genetic Information - (Sec. 202) Prohibits, as an unlawful employment practice, an employer, employment agency, labor organization, or joint labor-management committee from discriminating against an employee, individual, or member on the basis of genetic information, including: (1) for an employer, by failing to hire or discharging an employee or otherwise discriminating against an employee with respect to the compensation, terms, conditions, or privileges of employment; (2) for an employment agency, by failing or refusing to refer an individual for employment; (3) for a labor organization, by excluding or expelling a member from the organization; (4) for an employment agency, labor organization, or joint labor-management committee, by causing or attempting to cause an employer to discriminate against a member in violation of this Act; or (5) for an employer, labor organization, or joint labor-management committee, by discriminating against an individual in admission to, or employment in, any program established to provide apprenticeships or other training or retraining.

S.358, Genetic Nondiscrimination Act S.358, Genetic Nondiscrimination Act Title: A bill to prohibit discrimination on the basis of genetic information with respect to health insurance and employment. Title I: Genetic Nondiscrimination in Health Insurance - (Sec. 101) Amends the Employee Retirement Income Security Act of 1974 (ERISA) and the Public Health Service Act (PHSA) to specify that genetic information that an issuer of group health insurance may not establish as an enrollment eligibility factor includes information about a request for or receipt of genetic services by an individual or family member. Prohibits a group health plan or a health insurance issuer from: (1) adjusting premiums on the basis of genetic information; or (2) requesting or requiring an individual or a family member of such individual to undergo a genetic test.

H.R. 2638, Making appropriations for the Department of Homeland Security for the fiscal year ending September 30, 2008, and for other purposes.

H.R.3043, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2008, Title 2, all provisions relating to National Institutes of Health and National Center for Health Statistics S.1710, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2008, Title 2, all provisions relating to National Institutes of Health and National Center for Health Statistics

H.R.3043, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2008, Title 2, all provisions relating to National Institutes of Health and National Center for Health Statistics S.1710, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2008, Title 2, all provisions relating to National Institutes of Health and National Center for Health Statistics

H.R. 1188, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 S. 1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007

S.Res.116, A resolution designating May 2007 as "National Autoimmune Diseases Awareness Month" and supporting efforts to increase awareness of autoimmune diseases and increase funding for autoimmune disease research. H.Res.258, Expressing the sense of the House of Representatives that there should be established a National Autoimmune Diseases Awareness Month and for other purposes H.R.1188 and S.1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 Section 101. EXPANSION OF BIOMEDICAL RESEARCH • Directs the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) to expand and intensify research on psoriasis and psoriatic arthritis. • Directs NIAMS to coordinate with other National Institutes of Health (NIH) centers, institutes, and offices with respect to psoriasis and psoriatic arthritis research. Section 102. STRENGTHENING PSORIASIS AND PSORIATIC ARTHRITIS EPIDEMIOLOGY • Directs the Centers for Disease Control and Prevention (CDC), in collaboration with a national organization expert in the epidemiology of psoriasis and psoriatic arthritis, to establish a national psoriasis and psoriatic arthritis patient registry. Section 103. PSORIASIS AND PSORIATIC ARTHRITIS CO-MORBIDITIES CONDITIONS SUMMIT • Directs the Department of Health and Human Services (HHS) to convene a summit of researchers, public health professionals, patient advocacy organizations, academic institutions, and Federal and State policymakers to provide a detailed overview of current efforts in psoriasis and psoriatic arthritis research, treatment, quality of life, and other such activities at the NIH, CDC, the Agency for Healthcare Research and Quality, the Substance Abuse and Mental Health Services Administration, and the Health Resources and Services Administration, and other federal agencies whose work involves psoriasis and psoriatic arthritis related co-morbidities. • Requires a report to Congress – not later than 180 days after the convening of summit. H.R. 1188, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 S. 1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007

H.R.1188 and S.1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 Section 104. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE • Directs the HHS Secretary to enter into a contract with the Institute of Medicine (IOM) to conduct a study to evaluate and make recommendations to address the following: (1) The extent to which public and private insurers cover prescription medications and other treatments for psoriasis and psoriatic arthritis; (2) The payment structures, such as deductibles and co-payments, amounts and duration of the coverage and payments under health plans and their adequacy to cover the costs of providing ongoing care to patients with psoriasis and psoriatic arthritis; (3) Health plan and insurer coverage policies and practices and their impact on patient access to the best regimen and most appropriate care for their particular disease state. Access to care for people with psoriasis and psoriatic arthritis H.R. 1188, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 S. 1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007

* Access to care for people with psoriasis and psoriatic arthritis H.R. 1188, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 S. 1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 H.R. 2842 Childrens Health Protection Act of 2007 S. 2236 Childrens Health Protection Act of 2007 H.R. 2842 Childrens Health Protection Act of 2007 S. 2236 Childrens Health Protection Act of 2007

* Access to care for people with psoriasis and psoriatic arthritis H.R. 1188, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 S. 1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 H.R. 2842 Childrens Health Protection Act of 2007 S. 2236 Childrens Health Protection Act of 2007 H.R. 2842 Childrens Health Protection Act of 2007 S. 2236 Childrens Health Protection Act of 2007

S.Res.116, A resolution designating May 2007 as "National Autoimmune Diseases Awareness Month" and supporting efforts to increase awareness of autoimmune diseases and increase funding for autoimmune disease research. H.Res.258, Expressing the sense of the House of Representatives that there should be established a National Autoimmune Diseases Awareness Month and for other purposes H.R.1188 and S.1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 Section 101. EXPANSION OF BIOMEDICAL RESEARCH • Directs the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) to expand and intensify research on psoriasis and psoriatic arthritis. • Directs NIAMS to coordinate with other National Institutes of Health (NIH) centers, institutes, and offices with respect to psoriasis and psoriatic arthritis research. Section 102. STRENGTHENING PSORIASIS AND PSORIATIC ARTHRITIS EPIDEMIOLOGY • Directs the Centers for Disease Control and Prevention (CDC), in collaboration with a national organization expert in the epidemiology of psoriasis and psoriatic arthritis, to establish a national psoriasis and psoriatic arthritis patient registry. Section 103. PSORIASIS AND PSORIATIC ARTHRITIS CO-MORBIDITIES CONDITIONS SUMMIT • Directs the Department of Health and Human Services (HHS) to convene a summit of researchers, public health professionals, patient advocacy organizations, academic institutions, and Federal and State policymakers to provide a detailed overview of current efforts in psoriasis and psoriatic arthritis research, treatment, quality of life, and other such activities at the NIH, CDC, the Agency for Healthcare Research and Quality, the Substance Abuse and Mental Health Services Administration, and the Health Resources and Services Administration, and other federal agencies whose work involves psoriasis and psoriatic arthritis related co-morbidities. • Requires a report to Congress – not later than 180 days after the convening of summit. H.R. 1188, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 S. 1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007

* Access to care for people with psoriasis and psoriatic arthritis H.R. 1188, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 S. 1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 H.R. 2842 Childrens Health Protection Act of 2007 S. 2236 Childrens Health Protection Act of 2007 H.R. 2842 Childrens Health Protection Act of 2007 S. 2236 Childrens Health Protection Act of 2007

S.Res.116, A resolution designating May 2007 as "National Autoimmune Diseases Awareness Month" and supporting efforts to increase awareness of autoimmune diseases and increase funding for autoimmune disease research. H.Res.258, Expressing the sense of the House of Representatives that there should be established a National Autoimmune Diseases Awareness Month and for other purposes H.R.1188 and S.1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 Section 101. EXPANSION OF BIOMEDICAL RESEARCH • Directs the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) to expand and intensify research on psoriasis and psoriatic arthritis. • Directs NIAMS to coordinate with other National Institutes of Health (NIH) centers, institutes, and offices with respect to psoriasis and psoriatic arthritis research. Section 102. STRENGTHENING PSORIASIS AND PSORIATIC ARTHRITIS EPIDEMIOLOGY • Directs the Centers for Disease Control and Prevention (CDC), in collaboration with a national organization expert in the epidemiology of psoriasis and psoriatic arthritis, to establish a national psoriasis and psoriatic arthritis patient registry. Section 103. PSORIASIS AND PSORIATIC ARTHRITIS CO-MORBIDITIES CONDITIONS SUMMIT • Directs the Department of Health and Human Services (HHS) to convene a summit of researchers, public health professionals, patient advocacy organizations, academic institutions, and Federal and State policymakers to provide a detailed overview of current efforts in psoriasis and psoriatic arthritis research, treatment, quality of life, and other such activities at the NIH, CDC, the Agency for Healthcare Research and Quality, the Substance Abuse and Mental Health Services Administration, and the Health Resources and Services Administration, and other federal agencies whose work involves psoriasis and psoriatic arthritis related co-morbidities. • Requires a report to Congress – not later than 180 days after the convening of summit. H.R. 1188, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 S. 1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007

H.R. 1188, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 S. 1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007

H.R.1188 and S.1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 Section 104. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE • Directs the HHS Secretary to enter into a contract with the Institute of Medicine (IOM) to conduct a study to evaluate and make recommendations to address the following: (1) The extent to which public and private insurers cover prescription medications and other treatments for psoriasis and psoriatic arthritis; (2) The payment structures, such as deductibles and co-payments, amounts and duration of the coverage and payments under health plans and their adequacy to cover the costs of providing ongoing care to patients with psoriasis and psoriatic arthritis; (3) Health plan and insurer coverage policies and practices and their impact on patient access to the best regimen and most appropriate care for their particular disease state. Access to care for people with psoriasis and psoriatic arthritis H.R. 1188, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 S. 1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007

H.R.3043, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2008, Title 2, all provisions relating to National Institutes of Health and National Center for Health Statistics S.1710, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2008, Title 2, all provisions relating to National Institutes of Health and National Center for Health Statistics

H.R.3043, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2008, Title 2, all provisions relating to National Institutes of Health and National Center for Health Statistics S.1710, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2008, Title 2, all provisions relating to National Institutes of Health and National Center for Health Statistics

* Access to care for people with psoriasis and psoriatic arthritis H.R. 1188, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 S. 1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 H.R. 2842 Childrens Health Protection Act of 2007 S. 2236 Childrens Health Protection Act of 2007 H.R. 2842 Childrens Health Protection Act of 2007 S. 2236 Childrens Health Protection Act of 2007

S.Res.116, A resolution designating May 2007 as "National Autoimmune Diseases Awareness Month" and supporting efforts to increase awareness of autoimmune diseases and increase funding for autoimmune disease research. H.Res.258, Expressing the sense of the House of Representatives that there should be established a National Autoimmune Diseases Awareness Month and for other purposes H.R.1188 and S.1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 Section 101. EXPANSION OF BIOMEDICAL RESEARCH • Directs the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) to expand and intensify research on psoriasis and psoriatic arthritis. • Directs NIAMS to coordinate with other National Institutes of Health (NIH) centers, institutes, and offices with respect to psoriasis and psoriatic arthritis research. Section 102. STRENGTHENING PSORIASIS AND PSORIATIC ARTHRITIS EPIDEMIOLOGY • Directs the Centers for Disease Control and Prevention (CDC), in collaboration with a national organization expert in the epidemiology of psoriasis and psoriatic arthritis, to establish a national psoriasis and psoriatic arthritis patient registry. Section 103. PSORIASIS AND PSORIATIC ARTHRITIS CO-MORBIDITIES CONDITIONS SUMMIT • Directs the Department of Health and Human Services (HHS) to convene a summit of researchers, public health professionals, patient advocacy organizations, academic institutions, and Federal and State policymakers to provide a detailed overview of current efforts in psoriasis and psoriatic arthritis research, treatment, quality of life, and other such activities at the NIH, CDC, the Agency for Healthcare Research and Quality, the Substance Abuse and Mental Health Services Administration, and the Health Resources and Services Administration, and other federal agencies whose work involves psoriasis and psoriatic arthritis related co-morbidities. • Requires a report to Congress – not later than 180 days after the convening of summit. H.R. 1188, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 S. 1459, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007

H.R.3043, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2008, Title 2, all provisions relating to National Institutes of Health and National Center for Health Statistics S.1710, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2008, Title 2, all provisions relating to National Institutes of Health and National Center for Health Statistics

H.R.3043, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2008, Title 2, all provisions relating to National Institutes of Health and National Center for Health Statistics S.1710, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2008, Title 2, all provisions relating to National Institutes of Health and National Center for Health Statistics